

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			INVIT1280-1
			U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
			09/937837
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED	
PCT US00/08571	31 March 2000	31 March 1999	
TITLE OF INVENTION			
Delivery of Functional Protein Sequences By Translocating Polypeptides			
APPLICANT(S) FOR DO/EO/US			
Brian Dalby and Robert P. Bennett			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). Unexecuted</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. PTO-1449</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: Express Mail Certificate EL617042173US Copy of International Search Report Copy of International Preliminary Examination Report</p>			

U.S. APPLICATION NO. (if known) 09/937837 INTERNATIONAL APPLICATION NO. PCT US00/08571		ATTORNEY'S DOCKET NUMBER INVIT1280-1					
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO USE ONLY <table style="width: 100%; border: none;"> <tr> <td style="width: 60%; border: none;">\$1000.00</td> <td style="width: 40%; border: none;"></td> </tr> </table>		\$1000.00			
\$1000.00							
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		<table style="width: 100%; border: none;"> <tr> <td style="width: 60%; border: none;">\$ 130.00</td> <td style="width: 40%; border: none;"></td> </tr> </table>		\$ 130.00			
\$ 130.00							
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE				
Total claims	50 - 20 =	30	x \$18.00				
Independent claims	4 - 3 =	1	x \$80.00				
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00				
TOTAL OF ABOVE CALCULATIONS =			\$1750.00				
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+				
SUBTOTAL =			\$				
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$				
TOTAL NATIONAL FEE =			\$1750.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$				
TOTAL FEES ENCLOSED =			\$1750.00				
			<table style="width: 100%; border: none;"> <tr> <td style="width: 60%; border: none;">Amount to be refunded:</td> <td style="width: 40%; border: none;">\$</td> </tr> <tr> <td style="border: none;">charged:</td> <td style="border: none;">\$</td> </tr> </table>	Amount to be refunded:	\$	charged:	\$
Amount to be refunded:	\$						
charged:	\$						
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1750.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-1355</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.							
SEND ALL CORRESPONDENCE TO Lisa A. Haile, Ph.D. Gray Cary Ware & Freidenrich LLP 4365 Executive Drive, Suite 1100 San Diego, California 92121 USA (858) 677-1456 (858) 677-1465							
<div style="display: inline-block; vertical-align: bottom;"> SIGNATURE Richard J. Imbra NAME 37,643 REGISTRATION NUMBER </div>							

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dalby and Bennett Art Unit: Unassigned
Application No.: To be assigned Examiner: Unassigned
Filed: Herewith
Title: DELIVERY OF FUNCTIONAL PROTEIN SEQUENCES BY
TRANSLOCATING POLYPEPTIDES

Commissioner for Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §§ 1.821(f) and (g)

Sir:


I hereby state, as required by 37 C.F.R. § 1.821(f), that the information recorded in computer readable form is identical to the written sequence listing.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821 (g), herein does not include new matter.

Respectfully submitted,

Date:

September 28, 2001



Richard J. Imbra


Reg. No. 37,643

Telephone: (858) 677-1496

Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2189

Customer Number: 28213

CERTIFICATE OF MAILING BY "EXPRESS MAIL"	
"EXPRESS MAIL" LABEL NUMBER	EL617042173US
DATE OF DEPOSIT	September 28, 2001
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO BOX PATENT APPLICATION, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231	
Mikhail Bayley	
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER) (SIGNATURE OF PERSON MAILING PAPER OR FEE)	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Dalby and Bennett Art Unit: Unassigned
Application No.: To be assigned Examiner: Unassigned
Filed: Herewith
Title: DELIVERY OF FUNCTIONAL PROTEIN SEQUENCES BY
TRANSLOCATING POLYPEPTIDES

Commissioner for Patents
Washington, D.C. 20231

VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

I, Mikhail Bayley, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 09/28/2001

Mikhail Bayley
Mikhail Bayley

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1600
San Diego, CA 92121-2189

Customer Number: 28213

CERTIFICATE OF MAILING BY "EXPRESS MAIL"	
"EXPRESS MAIL" LABEL NUMBER	EL617042173US
DATE OF DEPOSIT	September 28, 2001
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO BOX PATENT APPLICATION, COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231	
Mikhail Bayley	<u>Mikhail Bayley</u>
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER) (SIGNATURE OF PERSON MAILING PAPER OR FEE)	

DELIVERY OF FUNCTIONAL PROTEIN SEQUENCES BY TRANSLOCATING POLYPEPTIDES

FIELD OF INVENTION

5

The present invention relates to methods for translocating polynucleotides and polypeptides between cells. More particularly, the present invention relates to use of translocating proteins to deliver a cell process-modifying molecule into the cell where the cell process-modifying molecule interacts specifically with a responsive target site.

10

BACKGROUND OF THE INVENTION

Translocating proteins are defined by their ability to cross biological membranes, such as cell membranes. A number of translocating proteins, have been described, including VP22 from Herpes Simplex Virus type 1 (G. Elliot and P. O'Hare, *Cell* 88, 223-233 (1997)), a fragment of the Antennapedia protein from *Drosophila* (Antp) (D. Derossi et al., *Journal of Biological Chemistry* 269, 10444-10450 (1994)), and Protein H from *Streptococcus pyogenes* (Axcrone et al., Manuscript in preparation (1999)).

15

Antennapedia is a homeoprotein with a DNA binding domain composed of three alpha helices with a beta-turn separating helix 2 and 3. Experiments have demonstrated that a 16 amino acid peptide corresponding to the third helix, named Antp, can translocate across membranes and accumulate in the cytoplasm and nucleus (Derossi et al, *supra*). This peptide is internalized at a temperature as low as 4°C, suggesting that endocytosis is not responsible for the internalization of the peptide. In addition, since translocation does not require classical endocytosis, Antp does not travel through the endosomal and lysosomal compartments. Therefore, Antp is resistant to proteolysis and has enhanced activity in most cellular compartments (D. Derossi et al., *J Biol Chem* 271:18188-18193, 1996).

20

25

Recent experiments showing that a reverse helix (*i.e.* the reverse primary sequence) and a helix composed of D-enantiomers can transverse plasma membranes at 4°C suggest that internalization of Antp involves the formation of inverted micelles

30

09/08/00 "484888"

in the phospholipid bilayer, making entry into cells receptor-independent and energy free (H. Hall et al., *Current Biol* 6:580-587, 1996).

The usefulness of Antp as a vector peptide has been proven successful by genetically fusing Antp to various peptides of interest (F. Perez et al., *J Cell Sci* 5 102:717-722, 1992; F. Perez et al., *Mol Endocrinol* 8:1278-87, 1994; and A. Prochiantz, *Curr Opin Neurob* 6:629-634, 1996) or by covalent linkage via cysteine residues (D. Derossi et al., *supra*). Internalization of peptides as large as 41 amino acids and of charged phosphopeptides (B. Allinquant et al., *J Cell Biol* 128:919-927, 1995) has been demonstrated in neuronal cells. In each case, the 10 sequences fused to Antp retained their expected biological functions. Furthermore, Antp is the only translocating peptide that has been used to deliver oligonucleotides (up to 45 nucleotides in length) to cells in culture (C.M. Troy et al., *J Neuro* 16 253-61, 1996; G. Elliot et al., *J Virol* 172:6448-6455, 1998).

Protein H is a surface antigen of the human pathogen *Streptococcus* 15 *pyogenes*. Protein H is taken up by B- and T-lymphocytes and translocated to the nucleus. In contrast to other translocating proteins, which appear to have no effect on cellular function, protein H has a cytostatic effect thought to be the result of its association with the nuclear proteins SET and hnRNP A2/B1 (D. Derossi et al., *supra*). To date, the translocation of Protein H coupled to another molecule has not 20 been demonstrated.

The best studied of the translocating proteins is the Herpes Simplex Virus protein VP22, which has the unique ability to translocate between cultured mammalian cells. When cells are transfected with a plasmid encoding the VP22 protein, the expressed protein accumulates in the cytoplasm of transfected cells and, 25 by translocating across cell membranes, spreads to the surrounding non-transfected cells where it accumulates in the nuclei. This process can occur at 4°C and also appears to be energy-free and independent of endocytosis. When protein trafficking though the cell is blocked using Brefeldin A, export of VP22 can still occur. Studies of cytoskeletal elements during VP22 trafficking suggest that the actin cytoskeleton 30 may be involved in export or import of VP22 (Elliot and O'Hare, *supra*).

Delivery of several functional VP22 fusion proteins has been described, including VP22-p53 (A. Phelan et al., *Nature Biotechnology* 16:440-443, 1998)) and VP22-thymidine kinase (M.S. Dilber et al., *Gene Therapy* 6:12-21, 1999). At least twenty different mammalian cell types can take up a functional VP22-GFP fusion protein (Elliot and O'Hare, supra; Aints A., et al., *J. Gene Med.* 1:275-9, 1999; and Wybranietz W. A. et al., *J. Gene Med.* 1:265-274, 1999), including mouse skeletal myoblasts that are refractory to conventional transfection techniques (Derer W. et al., *J. Mol. Med.* 77: 609-6138, 1999).

Transfection of cells with plasmid DNA has been an invaluable tool for the study of biological systems. A variety of transfection methods (e.g. lipids, calcium phosphate) exist in the marketplace; however, these methods rarely result in more than 50% of cells expressing a gene carried on a plasmid with which the cells are transfected. Since most cells do take up exogenous DNA, inefficient transfections do not appear to be due to inability of the DNA complex to enter the cell. The majority of DNA is internalized by endocytosis with very little of the internalized DNA ever reaching the cytoplasm or nucleus where expression takes place. Indeed, observations of directly injected lipid-DNA complexes suggest that movement from the endosomes to the cytoplasm and nucleus is the most important limitation to successful transfections (J. H. Richardson et al., *Proc. Natl. Acad. Sci.* 92:3137-3141, 1995). Consistent with this observation, peptides with membrane fusion activity, like the fusogenic peptide of hemagglutinin (J. Zabner et al., *Journal of Biological Chemistry* 270:18997-9007, 1995), or a nuclear targeting sequence (M. Wilke et al., *Gene Therapy* 3, 1133-1142 (1996)) can increase transfection efficiencies in some cases.

Thus, there is a need in the art for new and better methods for modulating expression in cells of target genes and for transfection reagents and methods of their use to overcome the major blocks to expression of transfected genes, i.e., degradation in the endosomes and the inability of DNA to enter the cell nucleus.

BRIEF DESCRIPTION OF THE INVENTION

The present invention overcomes these problems in the art by providing method(s) for modulating a cellular process in a cell in culture by contacting such a cell with a cell process-modifying molecule attached to a translocating polypeptide
5 under suitable conditions, whereby the cell process-modifying molecule is translocated into the cells in culture and interacts specifically therein with a target site responsive to the cell process-modifying molecule, thereby modulating a cellular process in the cell.

In another embodiment, the present invention provides method(s) for
10 transfecting a cell in culture with a target gene by contacting the cell under suitable conditions with a polynucleotide comprising the target gene attached to a translocating polypeptide, whereby the cell is transfected with the target gene.

In still another embodiment, the present invention provides method(s) for modulating expression of a target gene product in a cell in culture that is transfected
15 with the target gene under control of one or more regulatory elements by contacting the cell under suitable conditions with one or more regulatory agents attached to a translocating polypeptide, whereby the one or more regulatory agents are translocated into the cell and interact therein with the one or more regulatory elements, thereby modulating expression of the target gene product by the cell.

20 In yet another embodiment, the present invention provides vector(s) comprising a polynucleotide encoding a cell process-modifying molecule attached to a translocating polypeptide.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic drawing showing pFIN4/lacZ, which has an
25 intervening sequence (inv) flanked by Flp recognition sites (*frr*) separating the CMV promoter and β -galactosidase gene (*lacZ*). Interaction of Flp recombinase with pFIN4 results in the removal of the inv sequence and expression of β -galactosidase.

Figures 2A-D are schematic representations of the process by which a fusion protein composed of VP22, an anti-ATF-2 single chain antibody (sFv), and VP16 is delivered to the nucleus of a cell where it binds ATF-2 and activates transcription. **Figure 2A** shows the ATF-2/LexA DNA binding domain (DBD) fusion protein binds the LexA operator (Op) upstream of the minimal TK promoter and the luciferase reporter gene, but does not activate transcription. **Figure 2B** shows that the ATF-2 sFv-VP16 fusion protein binds ATF-2 and activates transcription. **Figure 2C** shows that the CREB sFv-VP16 fusion protein does not bind ATF-2 and cannot activate transcription. **Figure 2D** shows that the fusion protein composed of VP22, the ATF-2 sFv, and VP16 is delivered to the nucleus, where it binds ATF-2 and activates transcription.

Figures 3A-C show the attachment of a translocating protein (VP22) to an oligonucleotide (oligo) by generation of a bifunctional linker molecule. **Figure 3A** shows the chemical structure of a phenylboronic acid (PBA)-adapted nucleotide (PBA-dUTP). **Figure 3B** shows the chemical structure of a salicylhydroxamic acid (SHA)-adapted amino acid (R = lysine). **Figure 3C** shows the reaction of the PBA-adapted nucleotide and the SHA-adapted amino acid to create a bifunctional linker molecule that attaches the oligonucleotide to VP22.

Figure 4 is a schematic diagram illustrating a VP22-T7 RNA polymerase (T7 pol) expression system. VP22-T7Pol accumulates in the nucleus upon exogenous addition to tissue culture cells. In the nucleus, the VP22-T7 pol fusion protein recognizes the T7 promoter and activates transcription of gene X.

Figure 5 is a map of vector pVP22/Myc-His, which contains the T7 promoter (T7), VP22 open reading frame (VP22), a multiple cloning site, a myc epitope (*myc*), and a polyhistidine tag (6xHis).

Figures 6A and B show the nucleotide sequence of vector pVP22/Myc-His (SEQ ID NO:1).

Figure 7 is a map of pVP22/Myc-His-TOPO® vector, which contains the T7 promoter (T7), VP22 open reading frame (VP22), a multiple cloning site modified by

covalent coupling of the Vaccinia Virus Topoisomerase I protein (T) to linearized vector DNA, a myc epitope (*myc*), and a polyhistidine tag (6xHis). A PCR product with a single 3' A base overhang can be inserted into the topoisomerase-adapted site.

Figures 8A and B show the nucleotide sequence of pVP22/Myc-His-TOPO®
5 vector (SEQ ID NO:2).

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided method(s) for modulating a cellular process by contacting a cell in culture under suitable conditions with a cell process-modifying molecule attached to a translocating polypeptide,
10 whereby the cell process-modifying molecule is translocated into the cell and interacts specifically therein with a target site responsive to the cell process-modifying molecule, thereby modulating a cellular process in the cell.

As used herein, the term "translocating protein" means a protein, polypeptide, or functional fragment thereof, that crosses biological membranes. Translocating
15 proteins, polypeptides, functional fragments and homologues thereof, possess the following properties: resistance to proteolysis, receptor-independent penetration of cell membranes, and substantially energy-free penetration of cell membranes. Exemplary translocating proteins that can be used in the invention methods and constructs include VP22 from Herpes Simplex Virus type 1 (G. Elliot and P. O'Hare,
20 1997, *supra*), a fragment of the Antennapedia protein from *Drosophila* (Antp) (amino acids 43 through 58) (5'-RQIKIWFQNRRMKWKK-3') (SEQ ID NO:21) (Axcrone et al., *supra* 1999), Protein H from *Streptococcus pyogenes* (D. Derossi et al., *J. Biol. Chem.*, 271:18188-93, (1996)), and the like. While each translocating protein has distinct properties, the general application of translocating proteins is to deliver other
25 molecules to cells, either by constructing a fusion molecule (e.g., a fusion protein) or by attaching the desired molecule to the translocating protein (e.g. covalently or by means of a linker). In fusion proteins the translocating protein can be located either in the N-terminal or the C-terminal position. The preferred fusion protein or polypeptide for use in practice of the invention methods is a VP22 polypeptide.

The term "VP22 polypeptide" is used herein to refer to the herpes viral VP22 protein, as well as to functional fragments thereof, that have the translocating properties of the intact protein. In addition, the term "VP22 polypeptide" as used herein encompasses homologues of VP22 protein, such as those derived from
5 varicella zoster virus (VZV), equine herpesvirus (EHV), bovine herpesvirus (BHV), and the like, and transport-active (i.e. "functional") fragments, mutants and chimeric combinations thereof.

In particular, VP22 polypeptide encompasses polypeptides corresponding to amino acids 60-301 and 159-301 of the full HSV1 VP22 sequence (1-301), whose
10 sequence is disclosed in Figure 4 in WO 97/05265. Homologous proteins and fragments based on sequences of VP22 protein homologues from other herpes viruses are described in U.S. Patent 6,017,735, which is incorporated herein by reference in its entirety.

The term "fusion protein" as used herein refers to two distinct proteins,
15 polypeptides, peptides, and/or fragments not normally associated with each other in nature that are encoded by the same reading frame, resulting in the two or more distinct proteins and/or fragments being "fused" together. The fusion proteins used in invention methods are produced from nucleotide sequences encoding a translocating polypeptide, e.g., a VP 22 polypeptide, and another functional peptide in the same
20 reading frame. The polynucleotide encoding the fusion protein may also contain in the same reading frame additional peptide or polypeptide sequences useful in the invention methods, such as epitope-tag encoding sequences, affinity purification-tag encoding sequences, additional functional protein encoding sequences, and the like, or a combination of any two or more thereof.

25 In one embodiment, the invention provides method(s) for transfecting a cell with a target gene by contacting the cell under suitable conditions with a polynucleotide comprising the target gene attached to a translocating polypeptide, whereby the cell is transfected with the target gene. As used herein, the term "transfected" means that a gene translocated into a cell in culture due to the

translocating properties of an attached translocating polypeptide is expressed in the cell, at least transiently, i.e., the cell is transiently transfected with the target gene.

The size of polynucleotide that can be transfected into a cell according to the invention methods ranges from about 10 nucleotides to about 10 kilobases (kb). For example, polynucleotides in the range from about 20 nucleotides (nt) to about 5 kb, or from about 100 to 500 nt can be transfected into cells using the invention methods. Generally, the target polynucleotide is transiently transfected into a cell population in culture, for example, in a monolayer or tissue culture. None of the conventional means used to assist transfection or transduction is required, such as electroporation, infection employing viral vectors, calcium phosphate transfection, dextran sulfate transfection, lipofection, cytofection, particle bead bombardment, and the like. Instead, all that is required is contact (i.e., co-culture) of the cell population to be transfected with purified translocation protein or with synthetically prepared translocating protein having a polynucleotide of interest attached thereto by means of a covalent bond or linker molecule, as described herein. Any type of prokaryotic or eukaryotic cell in culture can be transfected using invention methods, for example, mammalian, yeast, insect or plant cells. However, it is presently preferred that the cells in culture be a monolayer of mammalian or insect cells.

In invention methods wherein a translocating protein is attached to plasmid DNA (i.e., via either covalent or non-covalent interactions), the DNA can be delivered to the nucleus for gene expression. Delivery of DNA using translocating proteins as described herein is an extremely valuable research tool. In up to 100% of the cells into which a desired polynucleotide containing an open reading frame (e.g., a polynucleotide contained in a plasmid) is delivered by an invention translocating protein, the polynucleotide is internalized, transported to the nucleus, and the open reading frame is then expressed, thus creating a homogeneous population of cells for studying such cell processes as cell cycle regulation, transcription regulation, translation regulation, and the like.

In another embodiment according to the invention, method(s) are provided for modulating expression of a target gene product in a cell in culture that contains a

target gene under control of one or more regulatory elements. In this embodiment, the invention method is practiced by contacting the cell in culture under suitable conditions with one or more regulatory agents attached to a translocating polypeptide, whereby the one or more regulatory agents are translocated into the cell in culture and
5 interact therein with the one or more regulatory elements, thereby modulating expression of the target gene product by the cell.

For example, a polynucleotide attached to a translocating polypeptide, such as VP22, can be translocated into the nucleus of the cell for expression of all or a part of the polynucleotide. In one embodiment, the polynucleotide comprises an open reading
10 frame encoding a protein of interest, such as a target gene product or reporter gene product. Alternatively, the polynucleotide can be a vector (e.g., a supercoiled plasmid) containing a cloned open reading frame that encodes a target gene.

It has been discovered that the translocating protein and attached cell process-modifying molecule can be directed to the cytoplasm for expression as well as to the
15 cell nucleus of the population of cells in culture if the translocating protein is attached (e.g., fused) to a nuclear export signal (NES). Signals for the export of proteins from the nucleus have recently been described. Analysis of PKI (heat stable inhibitor of cAPK, cyclic AMP-dependent protein kinase A) (Y. Wang et al., *Gene Therapy* 4, 432-441 (1997)) and the HIV Rev protein (W. Wen et al., *Cell* 82, 463-473 (1995))
20 has revealed a leucine rich sequence that is sufficient to direct heterologous sequences out of the nucleus and into the cytoplasm. Furthermore, fusion of the NES to a heterologous protein that includes the canonical SV40 larger T antigen NLS has been shown to result in the distribution of the protein between the cytoplasmic and nuclear compartments (Wang et al., *supra*). Similarly, the Rev protein contains sequences for
25 both nuclear import and export and is found in both the cytoplasmic and nuclear compartments of cells (Wen, et al, *supra*). Thus, incorporation of a NES is a potential method to modulate the nuclear targeting of translocating proteins, such as VP22, especially since the PKI NES can partially counteract the very strong signals of the SV40 NLS. When attached to a nuclear export signal, the translocating polypeptide
30 and any attached polynucleotide can be stably introduced into the cytoplasm as well

as the nucleus of the cells in culture, thereby accomplishing partition of the polynucleotide between cellular compartments. In the cytoplasm, regulation of expression of a gene contained in the polynucleotide can be regulated using invention methods as described herein.

5 Nuclear export signals suitable for use in the practice of the invention are known in the art and include the nuclear export signals derived from the HIV Rev protein or the heat stable inhibitor of cAPK, and the like. In many cases, inclusion of a nuclear export signal into the translocation protein-containing construct can be used to stably integrate a target gene of interest into the genome of the cells in culture.

10 A cell in culture can be contacted with a translocating protein attached to a cell-modifying molecule according to the present invention by a variety of methods. In the one method, an expression cell population transfected with a polynucleotide encoding the translocating protein fused to the cell-modifying molecule (e.g., as a fusion protein) is mixed and co-cultured with a target cell population that
15 spontaneously takes up the expressed translocation protein with attached cell-modifying molecule. The expressed protein accumulates in the cytoplasm of the transfected expression cells and, by translocating across cell membranes, spreads to the surrounding non-transfected cells where it accumulates in the nuclei. For example, the expression cell can be a prokaryotic cell line, such as E. coli, and the
20 target cell line can be any eukaryotic cell line, for example a mammalian cell line, such as CHO or COS, or an insect cell line, such as Drosophila S2, and the like.

Alternatively, the expression cell population can be cultured under conditions that promote expression of a transfected gene, a cell lysate can be prepared of the transfected expression cell population and the lysate can be applied to a cultured
25 target cell population using methods known in the art and as described in the Examples herein. When the translocation protein is VP22, the VP22 or fusion protein containing VP22 will translocate to the nuclei of substantially 100% of the cell population. It is also possible to culture the target cells with purified translocation protein-containing molecules or with synthetically prepared molecules containing the
30 translocating protein attached to a polypeptide or nucleotide by means of a covalent

bond or linker, as described herein. The translocating polypeptide and attached molecule will translocate to an entire cell population in culture within about 10 minutes to about 72 hours, more typically within about 10 minutes to about 50 hours; preferably within about 10 minutes to about 24 hours. However, in some cases, no
5 more than about 10 minutes is required for uptake of a translocating polypeptide and attached molecule by an entire cell population.

Fusions of translocating polypeptides with known DNA binding proteins can also be used to deliver DNA containing an open reading frame (e.g., a plasmid) to tissue culture cells. In this embodiment of the invention methods, the DNA binding
10 protein acts as a linker for attaching the translocating protein to the cell-modifying polynucleotide (i.e. a plasmid containing a polynucleotide that acts to modify a cell process). Examples of protein linkers that may be fused to translocating proteins for the delivery of polynucleotides, such as plasmid DNAs, include histone 1 (H1) protein (M. Wilke et al., *supra* and Niidome, et al., *J. Biol. Chem.* 272, 15307-15312 (1997))
15 and the non-histone protein HMG-17 (high mobility group 17) (S. V. Zaitsev, et al., *Gene Ther.* 4, 586-592 (1997)). HMG-17 interactions with DNA have been studied in depth and demonstrate that HMG-17 interacts with DNA in a non-cooperative, non-specific, and reversible manner (M. Bottger et al., *Arch. Geschwulstforsch* 60, 265-270 (1990)). In each case, either the entire DNA binding protein, or a functional
20 fragment thereof (i.e. a fragment having DNA binding activity) may be used.

It may be preferred to complex the DNA with a reagent, such as polyethylenimine (PEI), that condenses and neutralizes the charged DNA prior to mixing with the translocating protein, or translocating protein-DNA binding domain fusion.

25 Alternatively, if a shorter peptide linker is advantageous in the particular system used, the peptide linker may be fused to a translocating protein either as a chemically synthesized peptide or as a nucleotide encoding a fusion protein to be expressed in a prokaryote expression system. Examples of short peptide sequences that may be fused to a translocating protein either as a chemically synthesized peptide
30 or as a fusion protein include polylysine sequences and sequences containing three or

more repeats of the peptide sequence LARL, for example, LARL-LARL-LARL (SEQ ID NO:3) (J. D. Fritz et al., *Hum. Gene Ther.* 7:1395-1404 (1996)). In some cases, from three to about 100 repeats of the LARL sequence may be used as a linking peptide as described herein; typically from 3 to about 50 repeats, with 3 up to about 20 repeats being presently preferred.

A preferred linker for attaching a translocating protein to a cell-modifying polynucleotide is the Vaccinia virus topoisomerase I protein, or a mutant form thereof, which allows the formation of stable topoisomerase I-DNA conjugates. *Vaccinia* DNA topoisomerase, a 314 aa virus-encoded eukaryotic type I topoisomerase (I), binds to duplex DNA and cleaves the phosphodiester backbone of one strand (S. Shuman and B. Moss, *Proc. Natl. Acad. Sci. USA* 84: 7478-7482 (1987)). The enzyme exhibits a high level of sequence specificity, akin to that of a restriction endonuclease. Cleavage occurs at a consensus pentapyrimidine element 5'-(C/T)CCTT-3' in the scissile strand (S. Cheng et al., *Proc. Natl. Acad. Sci. USA* 91: 5695-5699 (1994); J.M. Clark, *Nucleic Acids Res.* 16: 9677-9686 (1988) ; and S.G. Morham and S.J. Shuman, *Biol. Chem.* 267: 15984-15992 (1992)). In the cleavage reaction, bond energy is conserved via the formation of a covalent adduct between the 3' phosphate of the incised strand and a tyrosyl residue (Tyr-274) of the protein. *Vaccinia* topoisomerase can religate the covalently held strand across the same bond originally cleaved (as occurs during DNA relaxation) or it can religate to a heterologous acceptor DNA and thereby create a recombinant molecule. When attached to an invention translocating protein, the *Vaccinia* topoisomerase I linker will attach to a double stranded oligonucleotide having single 5' A base overhangs, such as are created in Taq mediated PCR. Such topoisomerase I-DNA conjugates may then be introduced into cells.

Figure 7 illustrates a suitable vector wherein *Vaccinia* topoisomerase I linker is used to attach a translocating protein to a double-stranded oligonucleotide of interest. Vector pVP22/Myc-His TOPO® (SEQ ID NO:2), utilizes *Vaccinia* topoisomerase I linker to attach VP22 to a double stranded PCR product (i.e., a cell-process modifying oligonucleotide) having single 5' A base overhangs to create a VP22 fusion with

vector DNA. Such topoisomerase I-DNA conjugates may then be introduced directly into cells.

In another embodiment, a translocating protein is used to increase the efficiency of plasmid delivery in conjunction with a cationic liposome. Fusion of a translocating protein to a protein domain that readily associates with a cationic liposome, for example a hydrophobic transmembrane domain or a glycosylphosphatidylinositol (GPI) anchor, facilitates interaction at the lipid-DNA interface. Following endocytosis of the liposome-DNA complex, the translocating protein will translocate the complex through the endosomal membrane and into the cell cytoplasm and, eventually, to the nucleus for gene expression. Translocating proteins may also be used to enhance transfection efficiencies in conjunction with compounds, such as chloroquine, that inhibit lysosomal hydrolases (Niidome et al., *J. Biol. Chem.*, 272:5307-12, 1998).

Polynucleotides encoding fusion proteins may be constructed by standard molecular biology techniques (J. Sambrook, E. F. Fritsch and T. Maniatis (1989). *Molecular Cloning, A Laboratory Manual*. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY), transfected into tissue culture cells and tested for translocation ability by use of suitable methods, e.g., immunofluorescence, as are known in the art. See also the methods described in the Examples herein.

Inducible systems are used to study the phenotypic effects of protein expression. Since inducible systems allow expression of a protein on demand, such systems can be used as a research tool to study cell processes and even to enable the expression of toxic proteins in tissue culture. Current systems for inducible mammalian expression use transcriptional elements from diverse organisms, for example, *E.coli* (U. Fischer et al., *Cell* 82:475-483 (1995)), or *Drosophila* (M. Gossen et al., *TIBS* 18:471-475 (1993)) that are constitutively expressed in a cell line along with a vector that contains a promoter responsive to transcriptional regulators. Addition of an effector molecule causes binding of the transcriptional regulators to the inducible promoter, thus turning on gene expression.

The present invention provides a novel approach to this problem by providing method(s) for modulating expression of a target gene product in a mammalian cell transfected with the target gene under control of one or more regulatory elements. In the invention method, the target cell is contacted under suitable conditions with one or more regulatory agents attached to a translocating polypeptide, whereby the one or more regulatory agents are translocated into the mammalian cell and interact therein with the one or more regulatory elements, thereby modulating expression of the target gene product by the cell. The translocating polypeptide used in invention methods for modulating expression of a target gene product can be any of the translocating polypeptides disclosed herein, but is preferably a VP22 polypeptide.

The regulatory agent can be a polynucleotide, a protein or polypeptide, or a small molecule. For example, the regulatory element can be a promoter operatively linked to a target gene wherein translocation of the regulatory agent transactivates expression of the target gene product by the promoter. It is preferred that the regulatory agent be specific for the promoter, such as a polymerase specific for the promoter.

An exemplary inducible system according to the present invention utilizes the RNA polymerase of bacteriophage T7, which has been used to direct gene expression in mammalian cells. Expression of T7 RNA polymerase (T7 RNAP) by *Vaccinia* virus (A. Ramsey-Ewing and B. Moss, *J. Biol. Chem.* 271:16962-16966, 1996; T. R. Fuerst et al., *Proc. Natl. Acad. Sci.* 83:8122-8126, 1986) or in a stable cell line (O. Elroy-Stein and B. Moss, *Proc. Natl. Acad. Sci.* 87:6743-6747, 1990 and A. Lieber et al., *Nucleic Acids Res.* 17:8485-8493, 1989), or introduction of T7 RNAP protein at the time of transfection (X. Chen, et al., *Cancer Gene Ther.* 2:281-289, 1995 and X. Chen et al., *Nucleic Acids Res.* 22:2114-2120, 1994) promotes specific expression of genes that are located downstream of the small T7 promoter. The specificity that T7 RNAP has for the T7 promoter ensures that the desired gene is expressed and that non-specific gene activation does not occur. Expression using T7 RNAP has been reported to be very strong, 6-fold higher than the RSV promoter in one case (A. Lieber et al., *Nucleic Acids Res.* 17:8485-8493, 1989). In addition, gene expression

can be directed by T7 polymerase either in the nucleus (Lieber, *supra* and J. J. Dunn et al., *Gene* 68:259-266, 1988) or the cytoplasm of cells. These characteristics suggested that T7 RNAP can be used to specifically regulate gene expression by the addition of a T7 RNAP/VP22 fusion protein to cells containing a T7 promoter

5 construct. Direct delivery of T7 RNAP using VP22 technology allows specific control of gene expression and minimizes negative effects of delivery to non-target sites. Thus, the methods of the present invention allow for study of the phenotypic effects of protein expression on demand. Due to the specificity of the invention inducible system, the expression of toxic proteins can also be studied in tissue culture.

10 "Toxic proteins," as the term is used herein, refers to proteins that have immediate intrinsic toxic potential for living systems, including those trans-dominant mutations in proteins leading to constitutively active forms of the protein. Thus toxic proteins are distinguished from "pro-drug" type molecules that require modification after expression to release a toxic potential. Non-limiting examples of toxic proteins that

15 can be used in practice of the invention methods are various oncogene products, such as Raf and Ras oncogene products (Reviewed by Avruch et al. *Trends in Biology* 19:279-83, 1994).

Alternatively, the regulatory agent can be a transcription factor specific for the regulatory element so that translocation of the regulatory agent transactivates

20 expression of the target gene product. For example, the translocating protein can be fused to a DNA binding domain, such as that from the Gal4 protein, and to a common transactivation domain, such as VP16 or B42. In this embodiment of the invention, the translocating protein-containing fusion protein will localize to the nucleus and then specifically activate a promoter which contains upstream binding sites for the

25 DNA binding domain incorporated into the fusion protein.

"DNA-binding protein(s)" contemplated for use herein belong to the well-known class of proteins that are able to directly bind DNA and facilitate initiation or repression of transcription. Exemplary DNA-binding proteins contemplated for use herein include transcription control proteins (e.g., transcription factors and the like; see, for example,

30 Conaway and Conaway, *Transcription Mechanisms and Regulation*, Raven Press Series

on Molecular and Cellular Biology, Vol. 3, Raven Press, Ltd., New York, NY, 1994; T. Boulikas, *Critical Reviews in Eukaryotic Gene Expression*, 4(2&3):117-321, 1994; A. Klug, *Gene* 135:83-92, 1993; W. M. Krajewska, *Int. J. Biochem.*, 24:1885-1898, 1992.)

Transcription factors contemplated for use herein as a source of such DNA
5 binding domains include, e.g., homeobox proteins, zinc finger proteins, hormone receptors, helix-turn-helix proteins, helix-loop-helix proteins, basic-Zip proteins (bZip), β -ribbon factors, and the like. See, for example, S. Harrison, "A Structural Taxonomy of DNA-binding Domains," *Nature*, 353:715-719. Homeobox DNA-binding proteins suitable for use herein include, for example, HOX, STF-1 (Leonard *et al.*, *Mol. Endo.*,
10 7:1275-1283, 1993), Mat α -2, INV, and the like. See, also, Scott *et al.* *Biochem. Biophys. Acta*, 989:25-48, 1989. It has been found that a fragment of 76 amino acids (corresponding to amino acids 140-215 described in Leonard *et al.*, 1993) containing the STF-1 homeodomain binds DNA as tightly as wild-type STF-1. Suitable zinc finger DNA-binding proteins for use herein include Zif268, GLI, XFin, and the like. See also,
15 Klug and Rhodes, *Trends Biochem. Sci.*, 12:464, 1987; Jacobs and Michaels, *New Biol.*, 2:583, 1990; and Jacobs, *EMBO J.*, 11:4507-4517, 1992.

The DNA-binding domain(s) used in the invention methods can also be obtained from a member of the steroid/thyroid hormone nuclear receptor superfamily, or be substantially the same as those obtained from a member of the superfamily. The
20 DNA-binding domains of substantially all members of the steroid/thyroid hormone nuclear receptor superfamily are related. Such domains consist of 66-68 amino acid residues, and possess about 20 invariant amino acid residues, including nine cysteines. Members of the superfamily are characterized as proteins which contain these 20 invariant amino acid residues. The highly conserved amino acids of the DNA-binding
25 domain of members of the superfamily are as follows:

Cys - X - X - Cys - X - X - Asp* - X - Ala* - X - Gly* -
 X - Tyr* - X - X - X - X - Cys - X - X - Cys - Lys* - X -
 Phe - Phe - X - Arg* - X - X - X - X - X - (X - X -) Cys -
 X - X - X - X - X - (X - X - X -) Cys - X - X - X - Lys - X -
 5 X - Arg - X - X - Cys - X - X - Cys - Arg* - X - X -
 Lys* - Cys - X - X - X - Gly* - Met (SEQ ID NO:4);

wherein X designates non-conserved amino acids within the DNA-binding domain; an
 asterisk denotes the amino acid residues which are almost universally conserved, but for
 which variations have been found in some identified hormone receptors; and the residues
 10 enclosed in parenthesis are optional residues (thus, the DNA-binding domain is a
 minimum of 66 amino acids in length, but can contain several additional residues). Such
 DNA binding domains bind to 2-half site recognition sites, as is well known in the art to
 transactivate transcription under control of a response element comprising the
 recognition site.

15 The GAL4 DNA binding domain does not interact with a 2-half site DNA
 recognition site. The DNA binding domain of the yeast GAL4 protein comprises at least
 the first 74 amino terminal amino acids thereof (see, for example, Keegan *et al.*, *Science*
231:699-704, 1986). Preferably, the first 90 or more amino terminal amino acids of the
 GAL4 protein will be used, for example, the 147 amino terminal amino acid residues of
 20 yeast GAL4.

Another DNA binding domain that can be used in the practice of the present
 invention is the Tet operon. The tetracycline inducible system is well-known in the art
 (see, e.g, Gossen *et al.*, *Proc. Natl. Acad. Sci.* 89:5547-5551 (1992); Gossen *et al.*, *TIBS*
18:471-475 (1993); Furth *et al.*, *Proc. Natl. Acad. Sci.* 91:9302-9306, (1994) ; and
 25 Shockett *et al.*, *Proc. Natl. Acad. Sci.* 92:6522-6526 (1995)).

Transcription modulating domains are of two types, those that activate
 transcription of a gene sequence operatively associated with a response element that is
 responsive to the invention system (i.e., transcription activation domains) and those
 that repress or de-activate transcription of a gene sequence operatively associated with

a response element that is responsive to the invention system (i.e., transcription repression domains). The ability of the invention system to activate transcription of such a target gene is generally enhanced when the transcription modulating domain attached to the translocating protein is a transcription activation domain. Transcription
5 activation domains contemplated for use in the practice of the present invention can be obtained from a variety of sources and are well known in the art.

Such transcription activation domains are typically derived from transcription factors and comprise a contiguous sequence that functions to activate gene expression when associated with a suitable DNA-binding domain. For example, suitable activation
10 domains can be obtained from the N-terminal region of members of the steroid/thyroid hormone nuclear receptor superfamily, from transcription factor activation domains, such as, for example, VP16, GAL4, NF-kB or BP64 activation domains, and the like (See, for example, M. Manteuffel-Cymborowska, *Acta Biochim Pol.* 46(1):77-89 (1999); T. Tagami et al., *Biochem Biophys Res. Commun.* 253(2):358-63 (1998), W. Westin,
15 *Adv Pharmacol*, 47:89-112 (2000)). The activation domain presently preferred for use in the practice of the present invention is obtained from the C-terminal region of the VP16 protein.

Transcription repressor domains that can be used in the invention methods include those that repress transactivation of gene expression. Exemplary transcription
20 repressor domains suitable for use as the transcription modulating domain in the invention methods include RAFT, CREM, MECP-2, SMRT, NcoR, mSin3A, RAR, TR, SMRTR, and the like.

Another way in which translocating proteins may be used in inducible expression systems for modulating expression of a target gene is to create gene
25 fusions or in vitro covalent linkage with site-specific recombination sequences, which are sequences of nucleic acids that are specifically recognized by a particular site-specific recombinase. Site specific recombinases, as the term is used herein, are enzymes that catalyze the excision and/or recombination of nucleic acid sequences, and may form intermediate complexes with the transfer sequence DNA during the
30 recombination event. These enzymes recognize a relatively short, unique nucleic acid

sequence that serves as a site for both recognition and recombination. Recombinases particularly useful in the practice of the invention are those that function in a wide variety of cell types because such enzymes do not require any host specific factors and do not require ATP to function.

5 Two major families of site-specific recombinases from bacteria and unicellular yeast have been described: the integrase family and the resolvase/invertase family. In these recombinases, strand exchange catalyzed by site specific recombinases occurs in two steps of (1) cleavage and (2) rejoining, involving a covalent protein-DNA intermediate formed between the recombinase enzyme and the DNA strand(s). The
10 nature of the catalytic amino acid residue of the enzyme and the line of entry of the nucleophile is different for these two recombinase families. For cleavage catalyzed by the invertase/resolvase family, the nucleophile hydroxyl is derived from a serine and the leaving group is the 3'-OH of the deoxyribose. For the integrase family, the catalytic residue is a tyrosine and the leaving group is the 5'-OH. In both
15 recombinase families, the rejoining step is the reverse of the cleavage step.

The recombinase activity of Cre has been studied as a model system for the integrases. Cre is a 38 kD protein isolated from bacteriophage P1. It catalyzes recombination at a 34 base pair stretch of nucleic acids called loxP. The loxP site has the sequence 5'-ATAACTTCGTATAGCATAACATTATACGAAGTTAT-3' (SEQ ID
20 NO: 5; spacer region underlined), consisting of two 13 base pair palindromic repeats flanking an eight basepair core sequence (Hoess *et al.*, *Proc. Natl. Acad. Sci USA* 79:3398, 1982 and U. S. Patent No. 4,959,217, the disclosure of which is incorporated herein by reference in its entirety). The repeat sequences act as Cre binding sites with the crossover point occurring in the internal spacer core. Each repeat appears to bind
25 one protein molecule wherein the DNA substrate (one strand) is cleaved and a protein-DNA intermediate is formed having a 3'-phosphotyrosine linkage between Cre and the cleaved DNA strand. Crystallography and other studies suggest that four proteins and two loxP sites (each on a different DNA molecule) form a synapsed structure in which the DNA resembles models of four-way Holliday-junction
30 intermediates, followed by the exchange of a second set of strands to resolve the

intermediate into recombinant products (see, Guo, *et al.*, *Nature* 389:40-46, 1997). The asymmetry of the core region of the loxP recombination sequence is responsible for directionality of the recombination reaction. When two loxP sites on the same DNA molecule are in a directly repeated orientation, Cre excises the DNA between
5 these two sites, leaving a single loxP site on the DNA molecule (Abremski *et al.*, *Cell* 32:1301, 1983). Thus, the repeat sequences act as Cre-specific binding sites with the recombination crossover point occurring in the core.

The loxP site is so complex in size that it occurs only in the P1 phage genome. Therefore, use of the loxP sites in the invention methods assures that the enzyme will
10 not cut the transfer sequence within the interior of the sequence unless the transfer sequence is from the P1 phage genome. The activity of Cre in a wide variety of cellular backgrounds, including yeast, shows that Cre does not require host specific factors for activity (Sauer *Mol. Cell. Biol.* 7:2087-2096, 1987) in plant (Albert *et al.*, *Plant J.* 7:649-659, 1995; Dale and Ow, *Gene* 91:79-85, 1990; Odell *et al.*, *Mol. Gen.*
15 *Genet.* 223:369-378, 1990), or mammalian cells, including both rodent and human cells (van Deursen *et al.*, *Proc. Natl. Acad. Sci. USA* 92:7376-7380, 1995; Agah *et al.*, *J. Clin. Invest.* 100:169-179, 1997; Sauer and Henderson, *New Biologist* 2:441-449, 1990).

The Cre protein also recognizes a number of variant or mutant lox sites
20 (variant relative to the loxP sequence), including the loxB, loxL and loxR sites, which are found in the *E. coli* chromosome. Other variant lox sites include loxP511 (5'-ATAACTTCGTATAGTATACATTATACGAAGTTAT-3' (SEQ ID NO:6; spacer region underlined); loxC2 (5'-ACAACCTTCGTATAATGTATGCTATACGAAGTTAT-3' (SEQ ID NO:7; spacer region underlined; U.S. Patent No. 4,959,217). Additional variants of the loxP
25 site can be prepared by those of skill in the art and will generally have no more than a total of one to three point mutations in the two repeats that comprise the site-specific recombination sequence. Cre catalyzes the cleavage of the lox site within the spacer region and creates a six base-pair staggered cut. The two 13 bp inverted repeat
30 domains of the lox site represent binding sites for the Cre protein. The two lox sites

may differ so long as Cre is able to recognize both lox sites. However, if two lox sites differ in their spacer regions in such a manner that the overhanging ends of the cleaved DNA cannot reanneal with one another, Cre cannot efficiently catalyze a recombination event using the two different lox sites. The efficiency of the recombination event will depend on the degree and the location of the variations in the binding sites. For example, the loxC2 site can be efficiently recombined with the loxP site because the two lox sites differ by a single nucleotide in the left-binding site. Thus, when Cre is the site specific recombinase used in the practice of the invention methods, the site-specific recombination sequence is a loxP site, or a variant thereof recognized by the Cre enzyme.

A recombinase of the integrase family with similar function is Flp, a recombinase identified in strains of *Saccharomyces cerevisiae* that contain 2 μ -circle DNA. Flp recognizes a DNA sequence consisting of two 13 basepair inverted repeats flanking an 8 basepair core sequence (5'-GAAGTTCCTATTCTCTAGAAAGTATAGGAACTTC-3' (SEQ ID NO: 8); spacer underlined) called *FRT* (Flp Recombination Target site). A third repeat follows at the 3' end in the natural sequence, but does not appear to be required for recombinase activity. The Flp gene has been cloned and expressed in *E coli* and in mammalian cells (PCT International Patent Application PCT/US92/01899, Publication No: WO 92/15694, the disclosure of which is herein incorporated by reference) and has been purified (Meyer-Lean *et al.*, *Nucleic Acids Res.* 15:6469, 1987; Babineau *et al.*, *J. Biol. Chem.* 260:12313, 1985; Gronostajski and Sadowski, *J. Biol. Chem.* 260:12328, 1985).

Like Cre, Flp is functional in a wide variety of systems including bacteria (Huang *et al.*, *J. Bacteriology* 179:6076-6083, 1997), insects (Golic and Lindquist, *Cell* 59:499-509, 1989; Golic and Golic, *Genetics* 144:1693-1711, 1996), plants (Lyznik *et al.*, *Nucleic Acids Res* 21:969-975, 1993) and mammals (U. S. Patent Nos. 5,677,177 and 5,654,182), which shows the Flp does not require host specific factors for operability.

Additional integrases that can be used in practice of invention methods are retroviral integrases, including HIV and ASV integrases (Reviewed in Annu. Rev. Microbiol. 53:245-81, 1990).

In practice of invention methods for modulating expression of a target gene
5 produce, a site-specific DNA recombinase or integrase fused to a translocating protein
may be introduced as described herein into cells that have been transfected with a
plasmid containing a transcription-blocking sequence (e.g., a transcription termination
sequence) flanked by recombinase recombination sites specific for the recombinase or
10 integrase used and placed between a promoter and an open reading frame encoding a
target gene. For example, if the recombinase is Flp, the recombinase sites are *frt* sites,
and if the recombinase is Cre, the recombinase sites are *lox* sites. Exposure of the
transfected cell to the recombinase or integrase-adapted translocating protein results
in removal of the transcriptional terminator by the activity of the recombinase and
expression of the gene of interest as illustrated in Figure 1.

15 Thus, in the invention methods for modulating a cellular process, the one or
more regulatory elements can include a transcription-blocking sequence flanked by
recombinase recombination sites and the regulatory agent can be a recombinase
specific for the recombination sites, wherein translocation of the recombinase causes
recombination of the recombination sites, thereby modulating expression of the target
20 gene product.

Alternatively, rather than placing a pair of recombinase sites flanking a
polynucleotide segment to be excised, a single recombinase site can be incorporated
into (or exist naturally in) the genome of the target cell that also contains a plasmid
containing a target gene and a second recombinase site that pairs with the genomic
25 recombinase site. When such a cell is contacted by a recombinase (e.g. integrase)
specific for the recombinase site(s) in the target cell, translocation of the recombinase
will trigger a recombination event such that the target gene will become stably
incorporated into the genome of the target cell at the genomic recombinase site.

The recombinase or integrase may be introduced by mixing of two cell populations, one expressing the translocating protein-enzyme (e.g., Flp or Cre) fusion and the other containing the heterologous gene. Alternatively, the translocating protein-enzyme fusion may be produced in a prokaryotic or eukaryotic expression system, purified using known methods and as described herein, and applied to cells containing the heterologous gene. The cells may be either transiently transfected with the heterologous gene or carry it stably integrated in their genomes.

Alternatively, the regulatory agent used in invention methods for modulating gene expression can be the HIV Rev protein paired with the Rev regulatory element as regulatory element (RRE). As illustrated in Example 5 herein, increasing amounts of Rev protein delivered to target cells containing RRE result in increased expression of an operatively linked target gene.

In another embodiment of the invention method for modifying a cellular process, the protein molecule fused to a translocating protein is a Fv antibody fragment or a single chain antibody (sFv). Preferably polynucleotide encoding a fusion protein containing the translocating protein and sFv is introduced into cells in culture, as described herein, for translocation to the cell nucleus and intracellular expression. If the sFv is specific for an antigen target associated with intracellular machinery involved in a cellular function, for example, a target located within the cell nucleus, binding of the sFv to the intracellular target can interfere with cellular functions, such as Ras signaling (O. Elroy-Stein, T. R. Fuerst, B. Moss, *Proc. Natl. Acad. Sci.* **86**, 6126-6130 (1989), membrane transport (O. Cachet, et al., *Cancer Research* **58**, 1170-1176 (1998)), or viral replication (J. H. Richardson, J. G. Sodroski, T. A. Waldmann, W. A. Marasco, *Proc. Natl. Acad. Sci.* **92**, 3137-3141 (1995)). Additional exemplary intracellular targets for which single chain antibodies can be constructed and used in the invention methods to modify cellular processes include human kinases, transcription factors, proteins controlling apoptosis, cell cycle regulators, oncoproteins, and the like.

Therefore, the one or more regulatory agents used in the invention method(s) for regulating cell processes can include a Fv or sFv specific for a component of the

one or more regulatory elements within the cells in culture (whether the regulatory element is native or transfected into the cells), wherein translocation of the Fv or sFv into the cell by the translocating protein and binding of the antibody to the component modulates expression of the target gene product.

5 For example, intracellular processes have been modified by creating a fusion protein containing an anti-ATF-2 sFv fused to VP22 and the transcriptional activation domain of VP16 (Figures 2A-D). ATF-2 belongs to the bZIP family of transcription factors and controls gene expression via 8-bp ATF/CREB motifs, either as a
10 homodimer or as a heterodimer—for instance, with Jun (S. Huguier et al., *Molecular and Cellular Biology* 18:7020-7029, 1998). If the fusion protein is expressed within a reporter cell line that has ATF-2 bound upstream of a reporter gene, e.g., the bacterial luciferase gene, binding of the sFv in the fusion protein to the ATF-2 antigen in the cell nucleus (Figures 2A-D) triggers expression of the ATF-2 sFv-VP16 fusion (Figure 2B), but not a CREB sFv-VP 16 fusion (Figure 2C), resulting in expression of
15 the reporter gene. This experiment demonstrates that the ATF-2 sFv is delivered to the cell nucleus where it binds the ATF-2 antigen.

“Fv” as used herein means a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains but chemically linked; “sFv” as used herein means a genetically
20 engineered molecule containing the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

The linkage of light chain and heavy chain variable regions in a Fv may be noncovalent, as described in Inbar *et al.*, *Proc. Nat'l Acad. Sci. USA* 69:2659-62,
25 1972. Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde.

Exemplary linkers used to attach two segments of a Fv or to attach any other two proteins to (e.g., a translocating protein and a DNA binding protein) can be a bifunctional cleavable cross-linker, such as N-succinimidyl (4-iodoacetyl)-

- aminobenzoate; sulfosuccinimidyl (4-iodoacetyl)-aminobenzoate; 4-succinimidyl-oxycarbonyl- α -(2-pyridyldithio)toluene; sulfosuccinimidyl-6- [α -methyl- α -(pyridyldithiol)-toluamido] hexanoate; N-succinimidyl-3-(-2-pyridyldithio)-propionate; succinimidyl 6[3-(-2-pyridyldithio)-propionamido] hexanoate;
- 5 sulfosuccinimidyl 6[3-(-2-pyridyldithio)-propionamido] hexanoate; 3-(2-pyridyldithio)-propionyl hydrazide, Ellman's reagent, dichlorotriazinic acid, S-(2-thiopyridyl)-L-cysteine, and the like. Further bifunctional linking compounds are disclosed in U.S. Patent Nos. 5,349,066, 5,618,528, 4,569,789, 4,952,394, and 5,137,877, each of which is incorporated herein by reference in its entirety.
- 10 These linkers can be attached to purified proteins using numerous protocols known in the art, such as those described in Examples 1 and 2 (see Pierce Chemicals "Solutions, Cross-linking of Proteins: Basic Concepts and Strategies," Seminar #12, Rockford, IL).
- Preferably the antibodies used in the invention methods are sFv, comprising
- 15 V_H and V_L chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single
- 20 polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow and Filpula, *Methods*, 2: 97-105, 1991; Bird *et al.*, *Science* 242:423-426, 1988; Pack *et al.*, *Bio/Technology* 11:1271-77, 1993; and Ladner *et al.*, U.S. patent No. 4,946,778, which is hereby incorporated by reference in its entirety. Such well known procedures can be
- 25 modified to create fusion proteins comprising a sFv and a translocating protein, as described herein.

For example, the linker in the sFv can be a peptide having from about 2 to about 60 amino acid residues, typically from about 5 to about 40, preferably from about 10 to about 30 amino acid residues. This alternative is particularly

30 advantageous when the ligand moiety is proteinaceous. For example, the linker

moiety can be a flexible spacer amino acid sequence, such as those known in single-chain antibody research. Examples of such known linker moieties include GGGGS (SEQ ID NO:9), (GGGS)_n (SEQ. ID NO:10), GKSSGSGSESKS (SEQ ID NO:11), GSTSGSGKSSEGKG (SEQ. ID NO:12), GSTSGSGKSSEGSGSTKG (SEQ ID NO:13), GSTSGSGKSSEGKG (SEQ ID NO:14), GSTSGSGKPGSGEGSTKG (SEQ ID NO:15), EGKSSGSGSESKEF (SEQ ID NO:16), SRSSG (SEQ. ID NO:17), SGSSC (SEQ ID NO:18), and the like. A *Diphtheria* toxin trypsin sensitive linker having the sequence MGRSGGGCAGNRVGSSLSGGLNLQAM (SEQ ID NO:19) is also useful. Alternatively, the peptide linker moiety can be VM or AM, or have the structure described by the formula: AM(G_{2 to 4}S)_xAM wherein X is an integer from 1 to 11 (SEQ ID NO:20). Additional linking moieties are described, for example, in Huston *et al.*, *PNAS* 85:5879-5883, 1988; Whitlow, M., *et al.*, *Protein Engineering* 6:989-995, 1993; Newton *et al.*, *Biochemistry* 35:545-553, 1996; A. J. Cumber *et al.*, *Bioconj. Chem.* 3:397-401, 1992; Ladurner *et al.*, *J. Mol. Biol.* 273:330-337, 1997; and U.S. Patent. No. 4,894,443, the latter of which is incorporated herein by reference in its entirety.

It is contemplated to be within the scope of the present invention that the target gene within a cell in culture can be a reporter gene, such as is known in the art, for example, a non-endogenous gene encoding a detectable marker, such as the *E. coli* β-galactosidase gene, luciferase, or CAT.

As an aid in purifying the fusion molecules or detecting expression triggered by use of the invention methods, it is often convenient to include in the polynucleotide that encodes the reporter gene an additional nucleotide sequence that encodes a protein tag, such as an antibody epitope (e.g., derived from Myc), a fluorescent peptide, or a poly His tag.

A variety of methods can be used for attaching a peptide or oligonucleotide molecule to a translocating protein. For example, the translocating protein can be covalently conjugated to a translocating protein or to a polynucleotide encoding a translocating polypeptide for use in the invention methods using two low molecular weight chemical affinity ligands that can be attached to macromolecules like DNA

and to proteins and which combine to form a linker useful in preparation of fusion proteins or fusion genes used in the invention methods. Two such low molecular weight chemical affinity ligands are salicylhydroxamic acid (SHA) and phenylboronic acid (PBA), which quickly react to form a reversible pH-sensitive covalent bond (Figures 3A-C), thus providing a convenient linker to attach a translocating protein to another protein or to a polynucleotide. For example, nucleic acid molecules containing PBA can be synthesized using PBA-NTPs (available from ProLinx, Seattle, Washington) or, if double stranded, can be labeled with PBA-ATP using the enzyme terminal transferase. SHA-NHS ester can also be used to attach SHA to lysine residues present in a translocating protein. In this embodiment, a PBA-adapted molecule and a SHA-adapted translocating protein are covalently linked and applied to cells. Alternatively, other linkers, such as disulfide bonds (which would be disrupted upon delivery to the cytoplasm) or bifunctional linker molecules (e.g., as disclosed herein) may also be used. Covalent linking using these or other linkers known in the art and disclosed herein provides a relatively stable attachment of the translocating protein to another molecule.

In addition, a number of strong non-covalent molecular interactions can be used to generate translocating protein-containing complexes. For example, Streptavidin binds biotin very strongly (the disassociation constant is approximately 10^{-15}). This strong affinity, which is routinely used to attach proteins to substrates, can be used to form a linker that attaches a cell process-modifying molecule to a translocating polypeptide. For example, a fusion protein containing VP22 translocating protein and streptavidin may be generated and complexed with a biotinylated oligonucleotide to form a linker attaching a cell process-modifying polynucleotide to a translocating polypeptide. Streptavidin binds biotin as a tetramer (tetramer MW = 60,000 daltons) and VP22 is believed to act as a multimer, making this combination a suitable one.

Another polypeptide molecule that may be used as a linker to attach a cell process-modifying molecule to a translocating polypeptide for use in invention methods is the single stranded DNA binding protein (SSB) from *E coli*. Only

amino-acid residues (amino acid residues 2 through 22) of SSB appear to be involved in binding to ssDNA (i.e., "the functional fragment of SSB"). Furthermore, binding of SSB to ssDNA is not sequence specific. Therefore, a fusion protein containing a translocation protein fused to a functional fragment of SSB is an extremely attractive linker for attaching a translocating protein to an oligonucleotide or to plasmid DNA. Unlike the linking molecules described above (i.e., those containing PBA and SHA or streptavidin and biotin), which require modification of the oligonucleotide to be linked to the translocating protein, fusion proteins containing a SSB and a translocating protein can be attached to unmodified DNAs, thus providing time and cost-saving advantages.

The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLE 1

Introduction of VP22 fusion protein into cells in culture by transfection

The complete open reading frame (ORF) encoding the VP22 protein was cloned into the eukaryotic expression vector pcDNA3.1/myc-His (Invitrogen, San Diego, CA), to create the vector pVP22/Myc-His (Figure 5; SEQ ID NO:1), in which the ORF of the fusion partner can be inserted into a multiple cloning site located between the VP22 ORF and sequences encoding the C-terminal Anti-myc epitope and a poly His tag. The anti-myc epitope provides for easy detection of recombinant protein with Anti-myc antibody, and the poly His tag is useful for purification. Alternatively, the vector used was modified by covalent coupling of the Vaccinia Virus Topoisomerase I protein to linearized vector DNA (e.g., pVP22 TOPO® TA Cloning® Kit (Invitrogen)). In this type of vector, the ORF of a gene product of interest (i.e., a "fusion partner") was cloned as a PCR product into the vector. An example of such a Topoisomerase-adapted vector encoding the VP22 polypeptide is pVP22/Myc-His TOPO® vector (Figure 7; SEQ ID NO:2). In either case, the plasmid containing the VP22 gene fusion was then transfected into cells in culture

In a typical transfection, COS or CHO cells were seeded into 6 well plates and grown to approximately 50% confluence prior to transfection. For each well, 5 µg DNA was diluted into 1.5 ml OptiMEM medium (Gibco BRL, Chagrin Falls, OH) and mixed with 15 µl Pfx-6 lipid (Invitrogen) for COS cells or 15 µl Pfx-7 lipid (Invitrogen) for CHO cells. Diluted DNA plus lipid was incubated with cells for 4 hr at 37 °C, then replaced with the appropriate medium and incubated for an additional 40-48 hr at 37°C.

Spreading of the VP22 fusion protein from the transfected cells to the surrounding untransfected cells was detected by immunofluorescence using an antibody against the myc epitope tag. In a typical immunofluorescence experiment, transfected cells in a single 35 mm well of a six well tissue culture plate were washed with phosphate buffered saline (PBS) and fixed by incubation in 2 ml of methanol for 5 min. Cells were washed five times with PBS (2 ml/wash), blocked for 15 min using PBS containing 10% fetal bovine serum (FBS), and then incubated for 20 min with an antibody against the myc epitope tag (Invitrogen) diluted at 1:500 in 1 ml of PBS containing 10% FBS. For attachment of a fluorescent molecule to the antibody, cells were washed twice with PBS and incubated with a goat anti-mouse Oregon Green conjugate (Molecular Probes, Eugene, OR; cat # O-6383) diluted 1:500 in 1 ml of PBS containing 10% FBS for 20 minutes. After two additional washes, the antigen:antibody complexes were observed using an Olympus IX-70 fluorescence microscope equipped with a fluorescein isothiocyanate (FITC) filter.

Translocation of several VP22 fusion proteins prepared in this way, including those incorporating *Aequorea victoria* green fluorescent protein (hGFP), lacZ, or the site specific recombinase Fip as the fusion partner, has been achieved by this method.

EXAMPLE 2

Transfection of cells with a gene fusion followed by mixing with untransfected cells

To demonstrate how VP22 may be used to modulate expression of a functional gene product, a system for delivery of the site specific DNA recombinase Fip, was

developed. COS cells expressing a VP22-Flp recombinase fusion protein were prepared as described above and mixed with CHO cells that had been transfected with a reporter plasmid pFIN4/*lacZ* (Figure 1). In the reporter plasmid, a segment of DNA that includes a transcriptional terminator, the Bovine Growth Hormone polyadenylation signal (Goodwin and Rottman, *J. Biol. Chem.* 267:16330-4, 1992), is flanked by *frt* sites (recombination sites recognized by the recombinase Flp) to separate the CMV promoter and an otherwise operatively associated reporter gene encoding β -galactosidase as reporter. Cells transfected with pFIN4/*lacZ* did not express β -galactosidase due to the presence of the transcriptional terminator placed between the *frt* sites.

To illustrate that expression of the reporter gene could be controlled by translocating of the VP22-Flp recombinase fusion protein from one cell population to another, two populations of CHO cells were prepared, one transfected with plasmid that expresses the VP22-Flp recombinase fusion protein, and another transfected with plasmid that expresses a VP22-GFP fusion protein. Transfections were carried out as described above. Twenty-four hours after the end of the transfection, cells were recovered by trypsinization. Then the two cell lines were mixed and incubated for an additional 24 hr before staining for β -galactosidase activity.

CHO cells transfected with pFIN4/*lacZ* only expressed β -galactosidase when mixed with COS cells that express the VP22-Flp fusion. In the presence of Flp recombinase, the segment of DNA containing the transcriptional terminator was removed by recombination of the *frt* sites, and β -galactosidase was expressed. Incubation of the population of CHO cells transfected with plasmid that expresses a VP22-GFP fusion protein, but does not express a VP22-Flp fusion protein did not result in expression of β -galactosidase.

This experiment shows that the VP22-Flp fusion protein translocates between different mammalian cell types and that functional Flp recombinase can be delivered to cells as the fusion partner in a VP22 fusion protein.

EXAMPLE 3**Transfection of cells with a gene fusion followed by preparation of a cell free lysate from the transfected cells**

In these studies, a cell free lysate was prepared from cells transfected with pVP22/myc-His as follows: COS cells were grown to 50% confluence in a 100 mm dish (approximately 10^6 cells). Cells were transfected with 20 μ g of pVP22/myc-His DNA using Pfx-6. Forty hours post-transfection, the cell monolayer was washed twice with PBS and then collected by scraping into 10 ml PBS. Cells were centrifuged at 500 g for 5 min and the PBS was aspirated from the cell pellet, which was then frozen on dry ice. Frozen cell pellets were stored at -80°C prior to preparation of lysates. The cell pellet was thawed on ice following addition of 0.5 ml ice cold lysis buffer (10 mM HEPES, pH 7.9, 400 mM NaCl, 0.1 mM ethylene diaminetetraacetic acid (EDTA), 0.5 mM dithiothreitol (DTT), 5% glycerol). The lysate was then vortexed briefly and centrifuged at 10000 X g for 5 min at 4°C .

The entire supernatant was immediately added to 2×10^5 cells in a 35 mm plate without removing the tissue culture media. After a 10 minute incubation at 37°C , the media was removed and VP22/myc-His protein located in the nuclei of the cells was detected by immunofluorescence as described above.

An alternative method for the detection of VP22 fusion protein uptake in mammalian cells from a cell free lysate prepared from cells that express the fusion protein utilizes Western blot. In a typical Western blot experiment, HeLa, COS or CHO cells were plated at 50% confluence in 60 mm dishes. Following application of the lysate, the cells were washed once with PBS and then with PBS containing 500 mM NaCl to remove protein non-specifically bound to the outside of the cell. The cells were treated with trypsin for about 5 minutes to disassociate them from the plate and to digest any remaining extracellular peptide. The cells were solubilized and the proteins separated on a 4-20% Glycine gel (Invitrogen, Carlsbad, CA). The separated proteins were then transferred to nitrocellulose and probed with the appropriate

antibody conjugated to horseradish peroxidase (HRP). The VP22 fusion proteins were then detected using chemiluminescence.

Thus, the VP22/myc-His protein contained in the lysates of cells transfected with pVP22/myc-His translocated to the nuclei of all untransfected cells within 10 minutes of contact. This finding shows that lysates containing VP22 are useful for the delivery of protein sequences into cell types without the need for transfection of the receptor cell population.

EXAMPLE 4

Expression of a VP22 fusion protein in *E.coli*. followed by application of purified protein to cells in culture

The vector pCRT7/VP22-1 was developed to allow expression and purification of VP22 fusion proteins from *E. coli*. This vector utilizes a C-terminal fragment of the VP22 protein (amino acids 159-301), which has proven sufficient for translocation of VP22 fusion proteins across cell membranes. Using the above described methods, VP22 fusion proteins were prepared containing various proteins as the fusion partner (including the HIV Rev protein and human protein rhoA), and the fusion proteins were expressed and purified. Activity of each fusion partner was demonstrated following uptake by cells in culture. To demonstrate the high efficiency with which translocation occurs in cell cultures, even when the cells transfect poorly using conventional techniques, uptake of a VP22/GFP fusion proteins by Jurkat T-cells and PC12 cells, which are known to be refractory to standard transfection protocols, was also performed. These experiments show that VP22 fusion proteins can be purified and then delivered to substantially every cell in a cultured mammalian cell population, completely eliminating the need for transfection, even when the cell line is known to be refractory to standard transfection protocols.

pCRT7/VP22-1 is derived from the pET9b vector backbone (Novagen, Madison, WI). In preparation of pCRT7/VP22-1, the sequence encoding the C-terminal region of VP22 sufficient for translocation activity (amino acids 159-301), a fragment containing a multiple cloning site and myc and His tags from the vector

pVP22/myc-His were inserted into the pET9b vector backbone. The multiple cloning site of pCRT7/VP22-1 was derived from that of pVP22/myc-His. The pCRT7/VP22-1 vector was prepared for coupling to Vaccinia Topoisomerase I in exactly the same way as in preparation of the pVP22/myc-His-TOPO® plasmid, as described above. Therefore, in this vector, the sequence encoding the ORF of a fusion partner can be either inserted into one of the multiple cloning sites or cloned as a PCR product into the topoisomerase cloning site in a way similar to that used with pVP22/myc-His or pVP22/myc-His-TOPO® plasmid.

In a typical experiment a VP22 fusion protein was expressed as follows. Ten ng pCRT7/VP22-1 DNA was transformed into 50 µl BL21(DE3)plysS cells. The transformed cells were incubated at 37°C for 1 hour in 200 µl SOC medium, which was then diluted to 2 ml with Luria-Burtoni (LB) medium plus 50 µg/ml kanamycin and allowed to grow overnight at 37°C. The 2 ml culture was used to inoculate 50 ml LB medium containing 50 µg/ml kanamycin. Cells were allowed to grow until an optical density of 0.5 – 0.6 was attained and then allowed to continue growth at either 37°C, or shifted to room temperature (approximately 25°C) for 30 min. One ml of culture was removed and allowed to continue growing. Isopropyl-β-D-thiogalactopyranoside (IPTG) was added to the remaining culture to a final concentration of 1 mM. Cells were allowed to grow for an additional 4 hours and then gel samples were prepared from induced (plus IPTG) and non-induced cultures. 200 µl of each culture were removed, cells were recovered by centrifugation, and the pellets raised in 50 µl 1 X SDS/PAGE sample buffer. Alternatively, cells were recovered from the remainder of the culture by centrifugation and the cell pellets stored at -80°C.

The VP22 fusion protein was purified as follows: The cell pellet was thawed on ice and resuspended in 4 ml ice cold lysis buffer (50 mM Sodium Phosphate pH 8.0, 300 mM NaCl, 5 mM imidazole). The following were added to the lysis buffer immediately before cell lysis: β-mercaptoethanol to 5 mM, α-toluenesulfonyl fluoride (PMSF) to 0.5 mM, leupeptin and pepstatin to 1 µg/ml each, and lysozyme to 1 mg/ml. The lysate was incubated on ice for 20 to 30 min and then sonicated for

3 x 10 sec while on ice. DNase and RNase were added to final concentrations of 10 µg/ml each. The lysate was left on ice for an additional 20 min, then drawn through a 21 gauge needle three times, and centrifuged at 20000 g for 15 min. Following centrifugation, a gel sample was prepared from the soluble supernatant.

- 5 The supernatant was applied to a column containing 1 ml Probond resin equilibrated with lysis buffer (Probond beads interact with proteins tagged with 6 histidine arrays). The resin and supernatant were mixed in the column on ice for one to two hours. The column was then clamped vertically and the resin was allowed to settle.

- 10 A sample of the supernatant was removed to test for the presence of unbound protein by SDS/PAGE. The resin was washed by allowing 10 ml lysis buffer (50 mM Sodium Phosphate pH 8.0, 300 mM NaCl, 5 mM imidazole) to pass through the column. The lysis buffer was collected and a gel sample was removed. The column was then washed with 20 ml wash buffer (50 mM Sodium Phosphate pH 8.0, 300 mM NaCl, 40 mM imidazole, 10 % glycerol) and another gel sample was prepared in the
- 15 same way. Protein was eluted by addition of buffers having increasing concentrations of imidazole (wash buffer with either 100 mM, 200 mM or 500 mM imidazole). 3 ml of each buffer was applied, and 3 ml of each of the 100 mM and 200 mM imidazole elutions were collected. The 500 mM imidazole elution was collected as 0.5 ml fractions. A gel sample was also prepared from 10 µg of the resin after elution to
- 20 determine if the protein remained bound. All samples were examined on 4-20% SDS/PAGE gels (Novex) followed by Coomassie Staining or Western blot using an anti-myc-HRP conjugated antibody (Invitrogen) at 1:2000 dilution. Purified proteins were stored at 4°C for immediate use, or frozen at -80°C for storage.

- 25 Uptake of VP22 fusion proteins was detected by immunofluorescence. Cells were grown to approximately 50% confluence in 35 mm wells. The medium was then removed and replaced with 1 ml of serum free medium. Approximately 10 µg of the purified VP22 fusion protein, eluted in wash buffer containing 500 mM imidazole, was added directly to the serum-free medium. Cells were incubated at 37°C for 20 min and then washed with 3 x 2 ml PBS. Cells were then fixed and permeablized in

methanol for 5 min and prepared for immunofluorescence as described previously (see Invitrogen pVP22/myc-His Vector, cat no. V484-1).

Alternatively, uptake of VP22 fusion proteins was detected by Western blot. This technique was used to detect accumulation of VP22 fusion protein in the nuclei of PC12 cells and Jurkat T-cells. Suspensions of approximately 5×10^5 cells of each type were transferred to 15 ml Falcon tubes. Cells were recovered by centrifugation at 500 g for 5 min and then resuspended in 10 ml PBS. Cells were washed again in the same way, then resuspended in 1 ml serum-free medium containing approximately 10 μ g of the VP22/GFP fusion protein and incubated at 37°C for 15 min. Following the incubation, cells were washed twice by centrifugation and resuspended in 10 ml PBS as before described. Cells were recovered by centrifugation again, raised in 100 μ l ice cold lysis buffer (10 mM HEPES-KOH, pH 7.9, 1.5 mM $MgCl_2$, 10 mM, KCl, 0.5 mM dithio threitol (DTT), 1% Triton X-100), and incubated on ice for 10 min. The lysate was centrifuged at 10000 g for 10 min. The supernatant, containing soluble cytoplasmic proteins, was removed, and 4 X protein sample buffer was added to the supernatant. The pellet, containing cell nuclei, was resuspended in 100 μ l 1 X protein sample buffer. Samples were run on 4-20% SDS/PAGE gels (Novex) and transferred to nitrocellulose membrane. Western blots were probed with an anti-myc-HRP antibody conjugate (Invitrogen).

EXAMPLE 5

Activity of a VP22 fusion protein in recipient cells: functional testing of a VP22/Rev fusion protein

The HIV Rev protein is encoded by HIV genomic RNA and is responsible for regulation of RNA splicing. The Rev protein can bind to transcripts that contain a Rev Response Element (RRE), allowing export of the transcript from the nucleus and subsequent translation (reviewed in V. W. Pollard et al., *Ann. Rev. Microbiol.* 52:491-532, 1998). In the absence of Rev, transcripts that contain RRE will complex with the HIV spliceosome, but are not spliced. Instead, they remain in the nucleus and are degraded.

In the following experiment, the binding of Rev to the RRE in a transcript was used to activate expression of a reporter gene. A reporter plasmid (pCAT/RRE) was prepared that contains a CMV promoter and a CAT reporter gene separated by a splice donor site. The RRE was located on the 3' side of the CAT gene site.

- 5 Therefore, expression of CAT in response to Rev can be used to demonstrate the activity of Rev in the VP22/Rev fusion protein.

CHO cells were transfected with pCAT/RRE and then treated with either VP22/Rev fusion protein or VP22/myc-His control fusion protein. Expression of the CAT reporter gene was examined by Western blotting of protein samples prepared from treated cells, using an antibody against the CAT protein. A sample was also prepared from cells transfected with a CMV-CAT positive control plasmid that does not contain the RRE. Expression of the positive control could be detected. When cells were transfected with pCAT/RRE and then treated with VP22/myc-His control fusion protein, no expression of CAT could be detected. However, when cells transfected with pCAT/RRE were treated with VP22/Rev fusion protein, expression of CAT could be detected. When a five-fold larger amount of VP22/Rev protein was added, an apparent increase in the level of CAT protein was detected. These results show that VP22 can deliver functional Rev protein to the nucleus and lead to expression of a reporter gene.

20 In HIV infected cells, the Rev protein can shuttle between the cytoplasm and nucleus. The distribution of Rev between these intracellular compartments is dependent on a nuclear export signal present in the protein. To determine whether the nuclear export signal functioned in the invention VP22/Rev fusion protein, the distribution of VP22/Rev protein was examined by immunofluorescence using an antibody against the myc epitope tag, as described above. By this procedure, VP22/Rev fusion protein was detected in the cytoplasm and nuclei of cells, showing that fusion of Rev to VP22 appears not to interfere with the ability of Rev to be distributed to either the cytoplasm or the nucleus.

EXAMPLE 6**Delivery of one or more molecules into cells in order to modify cellular processes**

The following experiment demonstrates how a cellular process may be modified in a cell by delivery to the cell of a VP22 fusion protein that contains as the fusion partner the small GTPase, rhoA, which is involved in the polymerization of actin microfilaments in mammalian cells. Previous studies have shown that when Swiss 3T3 cells are starved of serum for 16 hr, actin microfilaments involved in maintaining the shape of cells depolymerize, leaving soluble actin monomers. Addition of serum causes rapid repolymerization of actin, restoring the microfilaments. This effect has been produced by microinjection of cells with activated rhoA protein that has been expressed and purified from *E. coli* (A. Hall, *Science* 279:509-514, 1998).

To test whether a VP22-rhoA fusion protein could generate a similar effect, a VP22-rhoA fusion protein was expressed and purified from *E. coli* using pCRT7/VP22-1-TOPO® plasmid. Swiss 3T3 cells were treated with the purified protein as follows: 3T3 cells were grown to approximately 50% confluence in 35 mm wells. Then the medium was removed and replaced with 1 ml of serum free medium. Cells were incubated for an additional 20 hr at 37°C. Approximately 1 µg of either purified VP22/rhoA or VP22/myc-His fusion protein was then applied to the cells. Twenty minutes later, cells were washed with 3 x 2 ml PBS, then fixed for 5 min in 4 % formaldehyde (from Invitrogen β-galactosidase Staining Kit). Cells were washed again with 3 x 2 ml phosphate buffered saline (PBS), permeablized for 5 min with 0.1% Tween-20® detergent in PBS, then washed again with 2 x 2 ml PBS. Cells were blocked for 30 min with 10% fetal bovine serum (FBS) in PBS before incubation with 0.1 µg/ml final concentration of FITC conjugated phalloidin (Sigma P-5282) in PBS/10% FBS for 30 min.

Phalloidin binds to polymerized actin more strongly than to depolymerized actin, thus allowing for visualization of repolymerized microfilaments. Cells were washed again with 2 x 2 ml PBS prior to observation with an Olympus fluorescence

microscope and FITC filter. The purified fusion protein was applied to serum-starved 3T3 cells. In cells that had been serum-starved and then treated with VP22/myc-His control fusion protein, no actin microfilaments could be detected and the cells appeared similar to serum-starved cells that had not been treated with either fusion protein. By contrast, in cells that had been treated with VP22-rhoA fusion protein for 20 minutes, actin microfilaments could be clearly detected by binding of phalloidin. The distribution of actin microfilaments in cells that had been treated with VP22-rhoA fusion protein appeared similar to that seen in cells that had neither been treated with a fusion protein nor serum-starved. These results indicate that VP22 can be used to deliver a functional rhoA fusion protein to cells.

The wild type rhoA protein appears to stimulate polymerization of actin microfilaments from the cell membrane, but VP22 protein is normally transported to the cell nucleus. Since VP22/rhoA could stimulate the polymerization of actin microfilaments in a similar way, the distribution of VP22/rhoA protein was examined by immunofluorescence using an antibody against the myc epitope tag of the protein (Invitrogen). Most of the VP22/rhoA fusion protein could be detected in the cytoplasm of recipient cells and very little protein appeared to reach the nuclei. These studies show that VP22/rhoA protein may be retained at the sites of rhoA activity and not completely translocated to the nucleus.

20

EXAMPLE 7

Delivery of a VP22 fusion protein to a specific cellular compartment by modification of VP22.

The following experiment demonstrates use of VP22 fusion protein to regulate distribution of the fusion partner within a specific cellular compartment. The HIV Rev protein (C. M. Troy et al., *Neuroscience* 16:253-61, 1996) contains a leucine rich sequence that is sufficient to direct heterologous sequences out of the nucleus and into the cytoplasm. Furthermore, it has been shown that fusion of the Nuclear Export Signal (NES) to a heterologous protein that includes the canonical SV40 large T antigen Nuclear Localization Signal results in distribution of the protein between the

cytoplasmic and nuclear compartments (W. Wen et al, *Cell* 82:463-473, 1995).

Similarly, the Rev protein contains sequences for both nuclear import and export and is found in both the cytoplasmic and nuclear compartments (U. Fischer et al., *Cell* 82:475-483, 1995).

- 5 To test the ability of a translocating protein to deliver a fusion partner to a cell location other than the cell nucleus, in the present experiment, a fusion protein that consists of VP22/myc-His with the eleven amino-acid Rev NES inserted between the VP22 ORF and the myc epitope tag was expressed in *E. coli*, purified as described above, and applied to cells in culture.
- 10 Distribution of the fusion protein among the cellular compartments in the cells in culture was examined by immunofluorescence as described above. The distribution of the fusion protein was verified by western blot analysis of treated cells, as follows: A suspension of 5×10^5 cells was transferred to 15 ml Falcon tubes. Cells were recovered by centrifugation at 500 g for 5 min and then resuspended in 10 ml PBS.
- 15 Cells were washed again in the same way, then resuspended in 1 ml serum-free medium containing approximately 10 μ g VP22/GFP fusion protein, and incubated at 37°C for 15 min. Following the incubation, cells were washed twice by centrifugation and resuspension in 10 ml PBS as before. Cells were recovered by centrifugation again and raised in 100 μ l ice cold lysis buffer (10 mM HEPES-KOH,
- 20 pH 7.9, 1.5 mM $MgCl_2$, 10 mM, KCl, 0.5 mM DTT, 1% Triton X-100® detergent) and incubated on ice for 10 min. The lysate was centrifuged at 10000 g for 10 min. The supernatant, containing soluble cytoplasmic proteins, was removed and supplemented with 4 X protein sample buffer. The pellet, containing cell nuclei, was resuspended in 100 μ l 1 X protein sample buffer. Samples were run on 4-20%
- 25 SDS/PAGE gels (Novex) and transferred to nitrocellulose membrane. Western blots were probed with an anti-myc-HRP antibody conjugate (Invitrogen). These tests show that Rev NES adapted-VP22-containing fusion protein can distribute into the cytoplasm and nuclei of treated cells.

EXAMPLE 8

Use of a VP22 fusion protein as a component of an inducible gene expression system.

To test the theory that a translocating protein can be used in an inducible gene expression system with great specificity, a T7 RNAP/VP22 fusion protein was expressed and purified from E. coli using a protocol similar that described above for other VP22 fusion proteins. RNA polymerase activity was examined in an *in vitro* transcription assay. All reagents were from an *in vitro* transcription kit (Ambion, Austin, TX), and were used according to the manufacturer's instructions. The amount of RNA produced by the presence of the T7 RNAP/VP22 fusion protein was found to be similar to that of the T7 RNAP included in the kit.

A reporter construct that contains a luciferase gene driven by a T7 promoter was also constructed. This construct was transfected into COS cells and 24 hours later purified T7 RNAP/VP22 fusion protein was applied to the cells. After an additional 24 hours, cell lysates were prepared and examined for luciferase enzyme activity using a luciferase assay kit (Promega) according to the manufacturer's instructions. Addition of T7 RNAP/VP22 fusion protein to cells transfected with the reporter gene resulted in five- to ten-fold increase above background in the level of luciferase expression, indicating that this system functions to control the expression of heterologous genes in eukaryotic cells.

EXAMPLE 9

Covalent and non-covalent coupling to translocating proteins.

Peptide or oligonucleotide molecules may be covalently conjugated to translocating proteins using Linx® chemical affinity system (Invitrogen) which uses low molecular weight chemical affinity ligands salicylhydroxamic acid (SHA) and phenylboronic acid (PBA). In this system, the low molecular weight chemical affinity ligands are used to form a bifunctional linker that attaches the translocating protein to a polynucleotide by means of a reversible pH-sensitive covalent bond.

Nucleic acid molecules containing PBA can be synthesized using PBA-NTPs (ProLinx, Seattle, WA) or, if double stranded, labeled with PBA-ATP using the enzyme terminal transferase. SHA-NHS ester can be used to attach SHA to lysine residues present in translocating proteins (Figures 3A-C). The PBA-adapted molecule and the SHA-adapted translocating protein are then covalently linked and administered to cells. A full description of the procedures and conditions used to link proteins using this system is publicly available (Linx™ Rapid Protein Conjugation Kit, Catalog Nos K8050-01 to K8060-01, Invitrogen, San Diego, CA).

EXAMPLE 10

10 Assay for uptake of translocating protein: oligonucleotide conjugates

A translocating protein and oligonucleotides of varying lengths can be conjugated and added exogenously to mammalian tissue culture cells. Single stranded DNA (ssDNA) of varying lengths containing PBA-ATP can be synthesized using PCR. A biotinylated 5' primer can be designed to allow purification of single-stranded molecules containing the PBA-ATP on a strepavidin column. A series of 3' reverse primers can be generated to facilitate the synthesis of a number of ssDNA molecules between 20 and 2000 nucleotides in length. The purified ssDNA molecules containing PBA will then be mixed with the translocating protein-SHA. Different concentrations of the protein: oligonucleotide conjugate can then added to cells and allowed to incubate for up to 4 hours. After incubation, the cells can be washed, fixed, and then probed using a strepavidin-FITC conjugate. Any internalized oligonucleotides will bind the strepavidin-FITC and be detected by fluorescence. It is expected that short oligonucleotides will be internalized very efficiently (*i.e.* delivered to 100% of the cells) and be concentrated within the nucleus.

25 While the invention has been described in detail with reference to certain preferred embodiments thereof, it will be understood that modifications and variations are within the spirit and scope of that which is described and claimed.

WHAT IS CLAIMED IS:

1. A method for modulating a cellular process, said method comprising contacting a cell in culture under suitable conditions with a cell process-modifying molecule attached to a translocating polypeptide, whereby the cell process-modifying molecule is translocated into the cell in culture and interacts specifically therein with a target site responsive to the cell process-modifying molecule, thereby modulating a cellular process in the cell in culture.
2. A method for transfecting a cell in culture with a target gene, said method comprising contacting the cell in culture under suitable conditions with a polynucleotide comprising the target gene attached to a translocating polypeptide, whereby the cell in culture is transfected by the target gene.
3. The method according to claim 2 wherein the translocating polypeptide is a VP22 polypeptide, Antp, or Protein H.
4. The method according to claim 2 wherein the translocating polypeptide is a VP22 polypeptide and the polynucleotide is translocated into the nucleus of the cell in culture.
5. The method according to claim 2 wherein the polynucleotide is linear or circular DNA containing a cloned open reading frame that encodes the target gene.
6. The method according to claim 5 wherein the polynucleotide is a supercoiled plasmid.
7. The method according to claim 2 wherein the translocating polypeptide is attached to a DNA binding protein and the DNA binding protein links the translocating polypeptide to the polynucleotide.

8. The method according to claim 7 wherein the DNA binding protein is histone 1 protein, high mobility group 17 protein (HMG17), a polylysine sequence, or an oligopeptide having at least three LARL repeats therein.
9. The method according to claim 2 wherein the translocating polypeptide is attached to a nuclear export signal and the polynucleotide is transfected into the cytoplasm as well as the nucleus of the cell in culture.
10. The method according to claim 9 wherein the nuclear export signal is derived from the HIV Rev protein or the heat stable inhibitor of cAPK.
11. The method according to claim 2 wherein the target gene is stably integrated into the genome of the cell in culture.
12. A method for modulating expression of a target gene product in a cell in culture that contains a target gene under control of one or more regulatory elements, said method comprising contacting the cell in culture under suitable conditions with one or more regulatory agents attached to a translocating polypeptide, whereby the one or more regulatory agents are translocated into the cell in culture and interact therein with the one or more regulatory elements, thereby modulating expression of the target gene product by the cell.
13. The method according to claim 12 wherein the cell in culture is a mammalian, yeast, insect or plant cell.
14. The method according to claim 12 wherein the translocating polypeptide has the properties of:
- resistance to proteolysis,
 - receptor-independent penetration of cell membranes, and
 - energy-free penetration of cell membranes.

15. The method according to claim 12 wherein the translocating polypeptide is a VP22 polypeptide, Antp, or Protein H.
16. The method according to claim 12 wherein the translocating polypeptide is a VP22 polypeptide.
17. The method according to claim 12 wherein the regulatory agent is a polynucleotide, a protein or polypeptide, or a small molecule.
18. The method according to claim 12 wherein the cell in culture is transfected with a polynucleotide comprising the target gene.
19. The method according to claim 14 wherein the regulatory element is a promoter and translocation of the regulatory agent transactivates expression of the target gene product by the promoter.
20. The method according to claim 19 wherein the regulatory agent is specific for the promoter.
21. The method according to claim 20 wherein the regulatory agent is a polymerase specific for the promoter.
22. The method according to claim 21 wherein the polymerase is T7 RNA polymerase and the promoter is a T7 promoter.
23. The method according to claim 12 wherein the regulatory agent is an HIV Rev protein and the regulatory element is the HIV Rev response element (RRE).
24. The method according to claim 12 wherein the regulatory agent is a transcription factor specific for the regulatory element and translocation of the regulatory agent transactivates expression of the target gene product.

25. The method according to claim 12 wherein the regulatory agent and the translocating polypeptide are covalently attached.
26. The method according to claim 12 wherein the regulatory agent and the translocating polypeptide are attached by a linker.
27. The method according to claim 26 wherein the linker comprises one or more disulfide bonds, salicylhydroxamic acid (SHA), phenylboronic acid (PBA), a SHA-NHS ester, or a combination thereof.
28. The method according to claim 12 wherein the translocating polypeptide and the regulatory agent are units of a fusion protein.
29. The method according to claim 12 wherein the regulatory agent is a single chain antibody (sFv).
30. The method according to claim 12 wherein the regulatory agent is a polynucleotide encoding a single chain antibody.
31. The method according to claim 12 wherein the translocating polypeptide and the regulatory agent are covalently linked by a biotin-streptavidin complex or the *E. Coli* single stranded DNA binding protein.
32. The method according to claim 12 wherein the cell line contains a single genomic recombination site and a plasmid containing the target gene and a recombination site that pairs with the genomic recombination site, and wherein the one or more regulatory agents includes a recombinase specific for the paired recombination sites, and wherein translocation of the recombinase causes recombination between the paired recombination sites resulting in stable integration of the target gene into the genome of the cell at the genomic recombinase site.

33. The method according to claim 32 wherein the recombinase is Flp and the recombinase sites are *frt* recombination sites.
34. The method according to claim 32 wherein the recombinase is Cre and the recombinase sites are *lox* recombination sites.
35. The method according to claim 12 wherein the one or more regulatory elements includes a transcription-blocking sequence flanked by recombinase recombination sites and the regulatory agent is a recombinase specific for the recombination sites, wherein translocation of the recombinase causes recombination of the recombination sites, thereby modulating expression of the target gene product.
36. The method according to claim 35 wherein the recombinase recombination sites are *frt* sites and the recombinase is Flp or the recombinase recombination sites are *lox* sites and the recombinase is Cre.
37. The method according to claim 12 wherein the one or more regulatory agents include a single chain antibody specific for a component of the one or more regulatory elements, wherein translocation of the single chain antibody in to the cell and binding of the antibody to the component modulates expression of the target gene product.
38. The method according to claim 12 wherein the target gene is a reporter gene.
39. The method according to claim 12 wherein the target gene is contained within a polynucleotide that further encodes a protein tag.
40. The method according to claim 12 wherein the target gene encodes a toxic protein.
41. The method according to claim 39 wherein the protein tag is a myc epitope, a fluorescent peptide, or a poly His tag, or a combination of any two or more thereof.

42. The method according to claim 12 wherein the contacting comprises mixing the mammalian or insect cell with an additional cell transfected with a polynucleotide that encodes the regulatory agent and the translocating polypeptide and the additional cell expresses the nucleotide to obtain the regulatory agent attached to the translocating polypeptide.

43. The method according to claim 42 wherein the additional cell is prokaryotic or eukaryotic.

44. The method according to claim 12 wherein the contacting involves incubating the cell line with a soluble protein lysate prepared from an additional transfected cell that expresses one or more polynucleotides encoding the regulatory agent and the translocating polypeptide.

45. The method according to claim 44 wherein the regulatory agent and the translocating polypeptide are expressed by the additional cell as a fusion protein.

46. The method according to claim 12 wherein the cell is refractory to other transfection techniques.

47. The method according to claim 12 wherein the cell is a member of a cell population and expression of the target gene is induced in substantially all of the cell population.

48. A vector comprising a polynucleotide encoding a cell process-modifying molecule attached to a translocating polypeptide.

49. The vector according to claim 48 wherein the vector is has a nucleotide sequence according to SEQ ID NO:1.

50. The vector according to claim 48 wherein the vector is has a nucleotide sequence according to SEQ ID NO:2

09637837.010702

1/10




FIGURE 1

2/10




FIGURE 2

3/10




FIGURE 3

4/10




FIGURE 4

5/10




FIGURE 5

6/10

GACGGATCGGGAGATCTCCCGATCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGATAGTT
 AAGCCAGTATCTGCTCCCTGCTTGTGTGGAGGTGCTGAGTAGTGCAGGAGCAAAATTTAAGCTACA
 ACAAGGCAAGGCTTGACCGACAATTCATGAAGAATCTGCTTAGGGTTAGGCGTTTTCGCTGCTTCGCG
 ATGTACGGGCGAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTC
 ATTAGTTCTAGCCCCATATATGGAGTTCGCGGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACC
 CCCAACGACCCCCGCGCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC
 ATTGACGTCAATGGGTGGACTATTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
 AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCGCTGGCATTATGCCCAGTACATGACCTTA
 TGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTGGC
 AGTACATCAATGGGCGTGGATAGCGGTTTGAATCAGGGGATTTCCAAGTCTCCACCCCATGACGTCAA
 TGGGAGTTTGTGTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCTGTAACAACTCCGCCCCATTGACG
 CAAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCA
 CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGTTAAGCTTATT
 ATGACCTCTCGCCGCTCCGTGAAGTCGGGTCCGCGGGAGGTTCCGCGCGATGAGTACGAGGATCTGTACT
 ACACCCGCTCTTCAAGTATGGCGAGTCCCGATAGTCCGCTGACACCTCCCGCGTGGCGCCCTACAGAC
 ACGCTCGCCCGCAGAGGGGCGAGGTCCGTTTCGTCAGTACGACGAGTCCGATTATGCCCTCTACGGGGC
 TCGTCTTCCGAAGACGACGAACACCGGAGGTCCCCCGGACGCGCGCTCCCGTTTCCGGGGCGGTTTGT
 CCGGCCCCGGGCTGCGCGGGCGCTCCGCCACCGCTGGGTCCGGAGGGGCGGACGACACCCACCAC
 CCCCCCGGGCCCCCGAACCAGCGGGTGGCGTCTAAGGCCCGCGCGCCCCGCGCGGCGGAGACACC
 CGCGGCGAGAAATCGGCCCCAGCCAGAATCCGCGCACTCCAGACGCCCCCGGCTCGACGGCGCCAACCC
 GATCCAAGACACCCGCGCAGGGGCTGGCCAGAAAGCTGCATTTAGCACCGCCCCCAAAACCCGAGCG
 GCATGGAGCCCCCGGGTGGCGGCTTTAACAAGCGGCTCTTCTGCGCCGCGGTGGGGCGCTGGCGGCG
 ATGCATGCCCGGATGGCGGCTGTCCAGCTCTGGGACATGTGCGTCCGCGCACAGACGAAGACCTCAACG
 AACTCTTGGCATCACCACTCCGCGTGACGGTCTGCGAGGGCAAAAACCTGCTTCAGCGCGCCACGA
 GTTGGTGAATCCAGACGTGGTGAGGACGTGACGCGGCCACGGGACTCGAGGGCGTTTGGCGGCTCG
 CGCCCCACCGAGCGACCTCGAGCCCCAGCCGCTCCGCTTCTGCGCCAGACGGCCCCGTCGAGGGTACCG
 AGCTCGGATCCACTAGTCCAGTGTGGTGAATTTCTGCAGATATCCAGCACAGTGGCGCGCGCTCGAGTCT
 AGAGGGCCCGGCTTGAACAAAACTCATCTCAGAAGAGGATCTGAATATGCATACCGGTCTATCATC
 CATCGCATTTAGTTTAAACCCGCTGATCAGCTCGACTGTGCTTCTAGTTGCCAGCCATCTGTTGTTT
 GCCCCCTCCCCGCTGCTTCTTGAACCTTGAAGGTGCCACTCCCACTGTCTTCTTAATAAAATGAGGA
 AATTGCATCGCATTTGTCTGAGTAGGTGTCTATTCTTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGG
 GAGGATTGGGAAGACAATAGCAGGCGATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAA
 CCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAGCGCGGCGGTGTGGTGGT
 TAGCGCGAGCGTGACCGCTACACTTGGCAGCGCCCTAGCGCCCGCTTCTGCTTCTTCCCTTCTCTT
 CTGCGCAGCTTCCGCGCTTCTCCCGTCAAGCTCTAAATCGGGGCTCCCTTAGGGTTCGAGTTTGTG
 CTTTACGGCACCTCGACCCCAAAAACTTGATTAGGGTGTGGTTACGTTAGTGGGCGATCGCCCTGATA
 GACGGTTTTCTGCGCTTTGACGTTGGAGTCCAGGTTCTTTAATAGTGGACTCTGTTTCCAACTGGAACA
 ACACTCAACCTATCTCGGTCTATTCTTTGATTATAAGGGATTGTTGGGATTTCGCGCTATTGTTAA
 AAAATGAGCTGATTAAACAAAATTTAACCGGAATTAATTTCTGTGGAATGTGTGAGTTAGGGTGTGGA
 AAGTCCCGAGGCTCCCGAGGCGAGCAGAAGTATGCAAGCATGCATCTCAATTAGTCAGCAACCAAGGTGT
 GGAAGTCCCGAGGCTCCCGAGGCGAGGATATGCAAGCATGCATCTCAATTAGTCAGCAACCATAG
 TCCCGCCCTTAACCTCGGCCATCCCGCCCTTAACCTCCCGCAGTTCCGCCCCATGCTTCCCGCCCTG
 ACTAATTTTTTTTATTTATGACAGGCGGAGGCGGCTCTGCTCTGAGCTATTCAGAGTAGTAGGA
 GGCTTTTTTGGAGGCTTAGGCTTTTGCAAAAGCTCCCGGGAGCTGTATATCCATTTTCGGATCTGATC
 AAGAGACAGGATGAGGATCGTTTCGATGATTGAACAAGATGGATTGACGAGGTTCTCCGCGCTGTC
 GGTGGAGAGGCTATTGCGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCGGTGTTCCGG
 CTGTGACGCGAGGGGCGCCGCTTCTTTTGTCAAGACCGACCTGCGGTGCCCTGAATGAATGACGAG
 ACGAGGCGAGCGCGCTATCGTGGCTGGCCAGGACGCGGCTTCTGCGCAGCTGTGCTCGACGTTGTAC
 TGAAGCGGAAGGGACTGGCTGCTATTGGGCGAAGTCCGCGGCGAGGATCTCTGTCTATCTCACCTTGCT
 CCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCC
 CATTGACCAACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCGGCTTTGTGATCA
 GGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACGTTCCGCCAGGCTCAAGGCGCGCATG
 CCCGACGCGAGGATCTCGTCTGACCCATGGCGATGCTGCTTCCGCAATATCATGTTGGAATAATGGCC
 GCTTTTCTGGATTCTGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTAC
 CCGTGATTTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCTCTGCTTTACGGTATCGCCGCT
 CCCGATTCCGAGCGCATCGCTTCTATCGCTTCTTGACGAGTTCTTCTGAGCGGACTCTGGGGTTCGC
 GAAATGACCGACCAAGCGACGCCCAACCTGCCATCAGAGATTTGATTTCCACCGCGGCTTCTATGAAA
 GGTGGGCTTTCGGAATCGTTTTCCGGGACGCGGCTGGATGATCTCCAGCGCGGGGATCTCATGTGGA
 GTTCTTCCGCCACCCCAACTTGTATTATGACGCTTATAATGTTTACAAATAAGCAATAGCATCAAAAT
 TTCACAAATAAGCATTTTTTCACTGCATTTAGTTGTGGTTTGTCCAACTCATCAATGTATCTTATC
 ATGTCTGTATACCGTCGACCTTAGCTAGAGCTTGGCGTAATCATGGTCTAGCTGTTTCTCTGTGTGAAA
 TTGTTATCCGCTCACAATTCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGGGTGCTAA
 TGAGTAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCAGTCCGGGAACCTGCTGTGCC
 AGCTCATTAATGAATCGGCCAACGCGGGGAGAGGCGGTTTGGGTATTGGGCGCTCTTCCGCTTCTCT
 GCTCACTGACTCGCTGCGCTCGGTGCTTCCGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATA
 CGGTTATCCAGAAATCAGGGGATAACGCGAGGAAGACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGA
 ACCGTAATAAGGCCGCTTGTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCAAAAAATCG

FIGURE 6A

7/10

ACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCC
CTCGTGCGCTCTCCTGTTCCGACCCTGCGCCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCG
TGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTTCGGTGTAGGTCGTTTCGCTCCAAGCTGGGCTG
TGTGCACGAACCCCCCGTTTACGCGGACCGCTGCGCTTATCCGGTAACATATCGTCTTGAGTCCAACCCG
GTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCG
GTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGC
TCTGCTGAAGCCAGTTACCTTCGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCCGCTGGT
AGCGGTGGTTTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGAAGATCCTTTGA
TCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATC
AAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTAAATCAATCTAAAGTATATATGAG
TAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTT
CATCCATAGTTGCGCTGACTCCCCGTGCTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAG
TGCTGCAATGATACCGCGAGACCCACGCTCACCCTCCAGATTTATCAGCAATAAACCCAGCCAGCCGGA
AGGGCCGAGCGCAGAAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATTAATTGTTGCCGGGAAG
CTAGAGTAAGTAGTTCCGCGAGTTAATAGTTTGGCGCAAGTTGTTGCCATTGCTACAGGCATCGTGGTGT
ACGCTCGTCTGTTTGGTATGGCTTCATTTCAGCTCCGTTCCCAACGATCAAGGCGAGTTACATGATCCCC
ATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCTCCGATCGTTGTGCAAGTAAGTTGGCCGCGAGTGT
TATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTATGCCATCCGTAAGATGCTTTTCTGT
GACTGGTGAGTACTCAACCAAGTCATTCTGAGAAATAGTGTATGCGGCGACCGAGTTGCTCTTGGCCGGCG
TCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAGTGCTCATCATTTGAAAACGTTCTTCGG
GGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTTCGATGTAACCCACTCGTGCACCCAACTG
ATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGAGCAAAAAACAGGAAGGCAAAATGCCGCAAAA
AAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGAAGCATTT
ATCAGGGTTATTGTCTCATGAGCGGATACATATTGAATGTATTTAGAAAAATAACAAATAGGGGTTCC
GCGCACATTTCCCCGAAAAGTGCCACCTGACGTC

FIGURE 6B

8/10




FIGURE 7

GACGGATCGGGAGATCTCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGCCGCATAGTT
 AAGCCAGTATCTGCTCCCTGCTTGTGTGGAGGTCGCTGAGTAGTGCGCGAGCAAAATTTAAGCTACA
 ACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCG
 ATGTACGGGCCAGATATACCGGTTGACATTGATTATGACTAGTTATTAAATAGTAATCAATTACGGGGTC
 ATTAGTTTCATAGCCCATATATGAGATTCCGCGTTACATAAATTACGGTAAATGGCCCGCTGGCTGACCG
 CCAACGACCCCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC
 ATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
 AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCCAGTACATGACCTTA
 TGGGACTTTCTTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTGGC
 AGTACATCAATGGGCGTGGATAGCGGTTTACTCACGGGGATTTCGAAGTCTCCACCCCATTTAGCGTCAA
 TGGGAGTTTGTTTTGGCACAAATCAACGGGACTTTCCAAATGTCTGTAACAATCCGCCCCATTGACG
 CAAATGGGCGGTAGGCGTGTACGGTGGGAGGTTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCA
 CTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGTTAAGCTTATT
 ATGACCTCTCGCGCTCCGTGAAGTCGGGTCCGCGGGAGGTTCCGCGCGATGAGTACGAGGATCTGTACT
 ACACCCCTCTTCAAGTATGGCGAGTCCGATAGTCCGCTGACACCTCCGCCCGTGGCGCTTACAGAC
 ACGCTCGCGCCAGAGGGGCGAGGTCGTTTCGTCAGTACGACGAGTCCGATTATGCCCTCTACGGGGC
 TCGTCTTCCGAAGACGACGAACACCCGGAGGTCCCGCGACGCGCGCTCCGTTTCCGGGGCGGTTTTGT
 CCGGCCCGGGGCTCGCGGGCGCTCCGCCACCCGCTGGGTCCGGAGGGGCGGACGACACCCACCAC
 CGCCCCCGGGCCCCCGAAACCCAGCGGGTGGCGACTAAGGCCCGCGGCCCGCGGGCGGAGACCAC
 CGCGCGCAGGAAATCGGCCCGAGCAGAATCCGCCGCACTCCAGACGCCCCCGCTCGACGGCGCAACCC
 GATCCAAGACACCCCGCGAGGGGCTGGCCAGAAAGCTGCACTTTAGCACCGCCCCCAACCCCGAGCG
 GCCATGGACCCCCCGGTGGCGGCTTTAACAAGCGCTCTTCTGCGCGCGGTTCGGGCGCTGGCGGCG
 ATGCATGCCCGGATGGCGGCGGTCCAGCTCTGGGACATGTGCGCTCCGCGCACAGACGAAGACCTCAACG
 AACTCTTGGCATCACCACTATCCGCGTACGGTCTGCGAGGGCAAAACCTGCTTCAGCGCGCCAACGA
 GTTGGTGAATCCAGACGTGGTGCAGGACGTGACGCGGCCACGGCGACTCGAGGGCGTTCTGGCGCTCG
 GCGCCACCGAGACCTCGAGCGCCAGCGCGCTCCGCTTCTCGCCCCAGACGCGCCGTCGAGGTACCG
 AGCTCGGATCCACTAGTCCAGTGTGGTGAATTTGCCCTTAAGGGCAATCTGCGAGATATCCAGCACAGT
 GCGGCGCTCGAGTCTAGAGGGCCCGCGGTTTCGAACAAAACCTCATCTCAGAAGAGGATCTGAATATGCA
 TACCGGTATCATCACCATCACCATTTGAGTTTAAACCCGCTGATCAGCTCGACTGTGCTTCTAGTTGC
 CAGCCATCTGTTGTTTGGCCCCCTCCCCCGTGCCTTCTTACCTGGAAGGTGCCACTCCACTGTCTCTT
 CCTAATAAAATGAGGAAATTCATCGCATTTGTCTGAGTAGGTGTCTATTCTGCGGGGTGGGGTGGG
 GCAGGACCAAGGGGAGGATTGGGAAGACAATAGCAGGATGCTGGGGATGCGGTGGGCTCTATGGCT
 TCTGAGGCGGAAAGAACCACTGAGGCTCTAGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAGCG
 CGGCGGCTGTGGTGGTTACGCGCAGCGTACCGCTACACTTGCACGCGCCCTAGCGCCCGCTCTTTCGC
 TTTCTTCCCTTCTTCTCGCCACGTTCCGCGGCTTTCCCGTCAAGCTCTAAATCGGGGCATCCCTTA
 GGGTCCGATTAGTCTTTACGGCACTCGACCCCAAAAACCTGATTAGGGGTGATGGTTACAGTAGTG
 GGCCATCGCCCTGATAGACGTTTTTCGCCCCCTTGACGTTGGAGTCCAGGTTCTTTAATAGTGGACTCTT
 GTTCCAACTGGAACAACACTCAACCTATCTCGGTCTATTCTTTTGATTATAAGGGATTGTTGGGATT
 TCGGCTTATGGTTAAATAATGAGCTGATTATAACAAAATTTAAGCGGAATTAATCTGTGGAATGTGTG
 TCAGTTAGGGTGTGGAAGTCCCCAGGCTCCCCAGGCGAGGAGATGCAAGCATGCATCTCAATTA
 GTCAGCAACCAAGGTGTGGAAGTCCCCAGGCTCCCCAGGCGAGGAGATGCAAGCATGCATCTCAAT
 TAGTCAGCAACCATAGTCCCGCCCTAATCCGCCCATCCCGCCCTAATCCCGCCAGTTCCGCGCAT
 CTCCGCCCATGGCTGACTAATTTTTTTTATTTATGACAGGGCCGAGGCGGCTCTGCCTCTGAGCTATT
 CCAGAAAGTAGTGAGGAGGCTTTTTTGGAGGCTTAGGCTTTTGCAAAAGCTCCCGGAGCTGTATATCC
 ATTTTCGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGATGGATTGCACGAG
 GTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCCGCTATGACTGGGCACAACAGACAATCGGCTGCTGTA
 TGCCCGCGTGTTCGGCTGTACGCGAGGGGCGCCCGGTTCTTTTGTAAGACCGACCTGTCGGGTGCC
 CTGAATGAAGTGCAGGACGAGGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCTTGGCGAGCTG
 TGCTCGAGCTTGTCACTGAAGCGGAAGGGACTGGCTGCTATTGGGCGAAGTCCCGGGGCGAGATCTCCT
 GTCATCTACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCCGCGGCTGCATACGCTT
 GATCCGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCAGTACTCGGATGGAAG
 CCGGCTTGTGCTAGTCAAGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACCTGTTCCGCG
 GCTCAAGGCGCGCATGCCGACGCGGAGGATCTCGTCTGACCCATGGCGATGCTGCTTCCGGAATATC
 ATGGTGGAATAATGGCCGCTTTCTGGATTCACTGACTGTGGCGGCTGGGTGTGGCGGACCGCTATCAGG
 ACATAGCGTTGGCTACCGGTGATATTGCTGAAGAGCTTGGCGGCAATGGGCTGACCGCTTCTCTGCTGCT
 TTACGGTATCGCGCTCCCGATTTCGACGCGCATCGCTTCTATCGCTTCTTGACGAGTTCTTCTGAGCG
 GGACTCTGGGGTTTCGGAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCGATTCCACC
 GCGGCTTCTATGAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGCTGGATGATCTCCAGCGCG
 GGGATCTCATGCTGGAGTTCTTCGCCACCCCAACTGTTTATTGACGCTTATAATGGTTACAAATAAAG
 CAATAGCATCACAAATTTACAAATAAAGCATTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTC
 ATCAATGTATCTTATCATGTCTGTATACCGTTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGC
 TGTTCCTGTGTGAAATTTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTA
 AGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTCCAGTCG
 GGAACCTGTCTGTCGACGTGCTAATGAATCGGCCAACGCGCGGGAGAGGCGGTTTGGCTATTGGGC
 GCTCTCCGCTTCTCGCTCACTGCTCGCTCGCTCGGTCGTTTGGCTGCGCGAGCGGTATCAGCTCA
 CTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCGAGGAAGACATGTGAGCAAAAGGC
 CAGCAAAAGGCCAGGAACCGTAAAGGGCCGCTTGTGGGTTTTTTCATAGGCTCCGCCCCCTGACG

FIGURE 8A

10/10

AGCATCAAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTT
TCCCCCTGGAAGCTCCCTCGTGGCTCTCCTGTTCCGACCCCTGCCGCTTACCGGATACCTGTCCGCTTT
CTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCCGGTGTAGGTCTGTC
GCTCCAAGCTGGGCTGTGTGCAGAAACCCCGTTTCAGCCCGACCGCTGCGCCTTATCCGGTAACATATCG
TCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGA
GCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAGGACAG
TATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAA
ACAAACACCGCTGGTAGCGGTGGTTTTTTTGGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGATCT
CAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAAACGAAACTCACGTTAAGGGATTT
TGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAAT
CTAAAGTATATATAGATAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCG
ATCTGTCTATTTCTGTCATCCATAGTTGCTGACTCCCGCTCGTGTAGATAACTACGATACGGGAGGGCT
TACCATCTGCCCCAGTGTGCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAAT
AAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAAGTGGTCTGCAACTTTATCCGCTCCATCCAGTCTATT
AATTGTTGCCGGGAAGCTAGAGTAAGTAGTTTCCGCACTTAATAGTTTGCAGCAACGTTGTTGCCATTGCTA
CAGGCATCGTGGTGTACGCTCGTCTGTTGGTATGGCTTCATTAGCTCCGTTCCCAACGATCAAGGCG
AGTTACATGATCCCCATGTTGTGCAAAAAGCGTTAGCTCCTTCGGTCCCTCCGATCGTTGTCAGAAGT
AAGTTGGCCGCGAGTGTATCACTCATGTTATGGCAGCACTGCATAATTCTCTTACTGTCTATGCCATCCG
TAAGATGCTTTTCTGTGACTGGTGAAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAG
TTGCTCTTGCCCGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATT
GGAAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTGATGTAAACCA
CTCGTGACCCAACTGATCTTCAGCATCTTTTACTTTACACAGCGTTTCTGGGTGAGCAAAAACAGGAAG
GCAAAATGCCGCAAAAAGGGAATAAGGGCGACACGGAATGTTGAATACTCATACTCTTCTTTTCAA
TATTATTGAAGCATTATCAGGGTTATTGTCTCATGAGCGGATACATATTGAATGTATTTAGAAAAATA
AACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTGACGTC

FIGURE 8B

ATTORNEY DOCKET NO.:
INVIT1280-1

DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **DELIVERY OF FUNCTIONAL PROTEIN SEQUENCES BY TRANSLOCATING POLYPEPTIDES**, the specification of which

 X is attached hereto.

 X was filed on September 28, 2001, (Attorney Docket No.:
INVIT1280-1)

as U.S. Application Serial No. _____ and was amended
on _____ if applicable (the "Application").

I hereby authorize and request insertion of the application serial number of the Application when officially known.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability of the subject matter of the Application as defined in Title 37, Code of Federal Regulations ("C.F.R."), § 1.56.

ATTORNEY DOCKET NO.:
INVIT1280-1

With respect to the Application, I hereby claim the benefit under 35 U.S.C.
Section 119(e) of any United States provisional application(s) listed below:

<u>60/127,467</u>	<u>March 31, 1999</u>
(Application Serial No.)	(Filing Date)
<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)
<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)



With respect to the Application, I hereby claim the benefit under 35 U.S.C.
Section 120 of any United States application(s), or Section 365(c) of any PCT International
application designating the United States, listed below and, insofar as the subject matter of
each of the claims of the application is not disclosed in the prior United States or PCT
International application in the manner provided by the first paragraph of 35 U.S.C.
Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark
Office all information known to me to be material to patentability of the subject matter of the
Application as defined in Title 37, C.F.R., Section 1.56 which became available between the
filing date of the prior application and the national or PCT International filing date of the
Application:

<u>PCT/US00/08571</u>	<u>March 31, 2000</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true
and that all statements made on information and belief are believed to be true; and further that
these statements were made with the knowledge that willful false statements and the like so

ATTORNEY DOCKET NO.:
INVIT1280-1

made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: **Brian Dalby**Inventor's signature: Date: 11/19/01Residence: Carlsbad, California CA.
Citizenship: U.S.A.Post Office Address: 2803 Unicornio Street
Carlsbad, CA 92009Full name of second inventor: **Robert P. Bennett**Inventor's signature: Date: 11/19/2001Residence: Encinitas, California CA.
Citizenship: U.S.A.Post Office Address: 1269 Rainbow Ridge Lane
Encinitas, California 92024Gray Cary\GT\6258668.1
102894-39

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dalby et al. Art Unit: Unassigned
Application No.: Unassigned Examiner: Unassigned
Filed: September 28, 2001
Title: Delivery of Functional Protein Sequences by Translocating Polypeptides

Commissioner for Patents
Washington, D.C. 20231

POWER OF ATTORNEY BY ASSIGNEE

As a below-named assignee of the above-identified application ("Application"):

I hereby appoint the following attorneys of the assignee to prosecute the
Application and to transact all business in the United States Patent and Trademark Office
connected therewith:

JAMES CLEARY	Reg. No. 45,843
CHARLES GAVRILOVICH, JR.	Reg. No. 41,031
LISA A. HAILE	Reg. No. 38,347
ERIC HOOVER	Reg. No. 37,355
RICHARD J. IMBRA	Reg. No. 37,643
SHEILA R. KIRSCHENBAUM	Reg. No. 44,835
JUNE M. LEARN	Reg. No. 31,238
ALAN LIMBACH	Reg. No. 39,749
GEORGE LIMBACH	Reg. No. 19,305
KARL LIMBACH	Reg. No. 18,689
TIMOTHY W. LOHSE	Reg. No. 35,255
TERRANCE A. MEADOR	Reg. No. 30,298
GERALD SEKIMURA	Reg. No. 30,103
STEVEN R. SPRINKLE	Reg. No. 40,825
DAVID R. STEVENS	Reg. No. 38,626
MARK TAKAHASHI	Reg. No. 38,631
EMANUEL J. VACCHIANO	Reg. No. 43,964
EDWARD WELLER	Reg. No. 37,468
RONALD YIN	Reg. No. 27,607
BARRY N. YOUNG	Reg. No. 27,744

In re Application of:

Dalby, et al.

PATENT

Attorney Docket No.: INVIT1280-1

Application No.: Unassigned

Filed: September 28, 2001

Page 2

Customer No. 28213

I hereby authorize and request insertion of the application number of the
Application when officially known.

Direct all telephone calls to:

LISA A. HAILE, J.D., PH.D.

Telephone: (858) 677-1456

Address all correspondence to:

LISA A. HAILE, J.D., PH.D.

GRAY CARY WARE & FREIDENRICH LLP

4365 Executive Drive, Suite 1100

San Diego, CA 92121

Invitrogen Corporation

By: 

Name: Alan W. Hammond

Title: Chief Intellectual Property Counsel

Date: 12/4/2001

SEQUENCE LISTING

<110> INVITROGEN CORPORATION
DALBY, Brian
BENNETT, Robert

<120> DELIVERY OF FUNCTIONAL PROTEIN SEQUENCES
BY TRANSLOCATING POLYPEPTIDES

<130> INVIT1280-1

<150> PCT/US00/08571

<151> 2000-03-31

<150> 60/127,467

<151> 1999-03-31

<160> 21

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 6404

<212> DNA

<213> Artificial Sequence

<220>

<223> vector pVP22/Myc-His

<400> 1

gacggatcgg	gagatctccc	gatcccctat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggtttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccggc	tggctgaccg	cccaacgacc	360
cccgcctatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggg	aaactgcccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catgggtgatg	cggttttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaattggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gctggctagt	900
taagcttatt	atgacctctc	gccgctccgt	gaagtcgggt	ccgcgggagg	ttccgcgcga	960
tgagtacgag	gatctgtact	acaccccgtc	ttcagggtatg	gcgagtcccg	atagtccgcc	1020
tgacacctcc	cgccgtggcg	ccctacagac	acgctcgcg	cagagggggc	aggtccgttt	1080
cgtccagtag	gacgagtcgg	attatgccct	ctacgggggc	tcgtcttccg	aagacgacga	1140
acaccgggag	gtcccccggg	cgcggcgctc	cgtttccggg	gcgggtttgt	ccggcccggg	1200
gectgcgcgg	gcgcctccgc	cacccgctgg	gtccggaggg	gccggacgca	cacccaccac	1260
cgcccccccg	gccccccgaa	cccagcgggt	ggcgcttaag	gcccccgcg	ccccggcggc	1320
ggagaccacc	cgcggcagga	aatcggccca	gccagaatcc	gccgcactcc	cagacgcccc	1380
cgcgtcgacg	gcgccaaccc	gatccaagac	acccgcgcag	gggctggcca	gaaagctgca	1440
cttttagcacc	gcccccccaa	accccgacgc	gccatggacc	ccccgggtgg	ccggctttta	1500
caagcgcgtc	ttctgcgcgc	cggtcggggc	cctggcgggc	atgcatgccc	ggatggcggc	1560
tgtccagctc	tgggacatgt	cgcgtccgcg	cacagacgaa	gacctcaacg	aactccttgg	1620
catcaccacc	atccgcgtga	cggctctgca	gggcacaaaac	ctgcttcagc	gcgccaacga	1680
gttggtgaat	ccagacgtgg	tgcaggacgt	cgacgcgggc	acggcgactc	gagggcgctt	1740

09/937837 010702

tgcggcgctcg	cgccccaccg	agcgacctcg	agccccagcc	cgctccgctt	ctcgccccag	1800
acggcccgtc	gaggggtaccg	agctcggatc	cactagtcca	gtgtggtgga	attctgcaga	1860
tatccagcac	agtggcgggcc	gctcgagtct	agagggcccg	cggttcgaac	aaaaactcat	1920
ctcagaagag	gatctgaata	tgcataccgg	tcatcatcac	catcaccatt	gagtttaaac	1980
ccgctgatca	gcctcgactg	tgccttctag	ttgccagcca	tctgttgttt	gcccccccc	2040
cgtgccttcc	ttgaccctgg	aaggtgccac	tcccactgtc	ctttcctaata	aaaatgagga	2100
aattgcatcg	cattgtctga	gtaggtgtca	ttctattctg	gggggtgggg	tggggcagga	2160
cagcaagggg	gaggattggg	aagacaatat	caggcatgct	ggggatgcgg	tgggctctat	2220
ggcttctgag	gcggaaagaa	ccagctgggg	ctctaggggg	tatccccacg	cgccctgtag	2280
cggcgcatca	agcgcgggcg	gtgtggtggt	tacgcgcagc	gtgaccgcta	cacttgccag	2340
cgccttagcg	cccgtccttt	tgcctttctt	cccttccttt	ctcgccacgt	tgcgcggctt	2400
tcccgtcaa	gctctaaatc	ggggcatccc	tttagggttc	cgatttagtg	ctttacggca	2460
cctcgacccc	aaaaaacttg	attaggggtga	tggttcacgt	agtgggcat	cgccctgata	2520
gacggttttt	cgccctttga	cgttggagtc	cacgttcttt	aatagtggac	tcttgttcca	2580
aactggaaca	acactcaacc	ctatctcggt	ctattctttt	gatttataag	ggattttggg	2640
gatttcggcc	tattgggttaa	aaaatgagct	gatttaacaa	aaatttaacg	cgaattaatt	2700
ctgtggaatg	tgtgtcagtt	agggtgtgga	aagtccccag	gctccccagg	caggcagaag	2760
tatgcaaagc	atgcatctca	attagtcagc	aaccagggtg	ggaaagtccc	caggctcccc	2820
agcaggcaga	agtatgcaaa	gcattgcatt	caattagtca	gcaaccatag	tcccggccct	2880
aactccgccc	atcccccccc	taactccgcc	cagttccgcc	cattctccgc	cccatggctg	2940
actaattttt	tttattttatg	cagaggccga	ggccgcctct	gcctctgagc	tattccagaa	3000
gtagttagga	ggcttttttg	gaggcctagg	cttttgcaaa	aagctcccgg	gagcttgtat	3060
atccattttc	ggatctgatc	aagagacagg	atgaggatcg	tttcgcatga	ttgaacaaga	3120
tggattgcac	gcaggttctc	cggccgcttg	ggtggagagg	ctattcggct	atgactgggc	3180
acaacagaca	atcggctgct	ctgatgccgc	cgtgttcggg	ctgtcagcgc	agggggcgcc	3240
ggttcttttt	gtcaagaccg	acctgtccgg	tgcctgaat	gaactgcagg	acgaggcagc	3300
gcggctatcg	tggctggcca	cgacggcggt	tccttgccga	gctgtgctcg	acgttgtcac	3360
tgaagcggga	agggactggc	tgctattggg	cgaagtgcgg	gggcaggatc	tcctgtcatc	3420
tcaccttgct	cctgccgaga	aagtatccat	catggctgat	gcaatgcggc	ggctgcatac	3480
gcttgatccg	gctacctgcc	cattcgacca	ccaagcgaaa	catcgcatcg	agcgagcacg	3540
tactcggatg	gaagccgggtc	ttgtcgatca	ggatgatctg	gacgaagagc	atcaggggct	3600
cgcgccagcc	gaactgttcg	ccaggctcaa	ggcgcgcatg	cccgcggcg	aggatctcgt	3660
cgtgacccat	ggcgatgcct	gcttgccgaa	tatcatggtg	gaaaatggcc	gcttttctgg	3720
attcatcgac	tgtggccggc	tgggtgtggc	ggaccgctat	caggacatag	cgttggctac	3780
ccgtgatatt	gctgaagagc	ttggcgggca	atgggctgac	cgcttcctcg	tgctttacgg	3840
tatcgccgct	cccgatctcg	agcgcatcgc	cttctatcgc	cttcttgacg	agttctctg	3900
agcgggactc	tggggtttcg	gaaatgaccg	accaagcgac	gcccacacctg	ccatcacgag	3960
atttcgattc	caccgcggcc	ttctatgaaa	ggttgggctt	cggaatcggt	ttccggggacg	4020
ccggctggat	gatcctccag	cgcggggatc	tcattgctgga	gttcttcgcc	caccccaact	4080
tgtttattgc	agcttataat	ggttacaaat	aaagcaatag	catcacaat	ttcacaata	4140
aagcattttt	ttactgcat	tctagtgtg	gtttgtccaa	actcatcaat	gtatcttata	4200
atgtctgtat	accgtcgacc	tctagctaga	gcttggcgta	atcatggtca	tagctgtttc	4260
ctgtgtgaaa	ttgttatccg	ctcacaattc	cacacaacat	acgagccgga	agcataaagt	4320
gtaaagcctg	gggtgcctaa	tgagttagct	aactcacatt	aattgcgttg	cgctcactgc	4380
ccgctttcca	gtcgggaaac	ctgtcgtgcc	agctgcatta	atgaatcggc	caacgcgcgg	4440
ggagaggcgg	tttgcgtatt	gggcgctctt	cgcttctctc	gctcactgac	tcgctgcgct	4500
cggctcgttc	gctgcggcga	gcgggtatcag	ctcactcaaa	ggcggttaata	cggttatcca	4560
cagaatcagg	ggataacgca	ggaaagaaca	tgtgagcaaa	aggccagcaa	aaggccagga	4620
accgtaaaaa	ggccgcgttg	ctggcgtttt	tccataggct	ccgccccct	gacgagcatc	4680
acaaaaatcg	acgctcaagt	cagagggtggc	gaaacccgac	aggactataa	agataaccagg	4740
cgtttcccc	tggagctcc	ctcgtgcgct	ctcctgttcc	gacctgcgg	cttaccggat	4800
acctgtccgc	ctttctccct	tcgggaagcg	tggcgctttc	tcaatgctca	cgctgtagg	4860
atctcagttc	ggttgtaggtc	gttcgctcca	agctgggctg	tgtgcacgaa	cccccgctt	4920
agcccgaccg	ctgcgcctta	tccggtaact	ctcgtcttga	gtccaacccg	gtaagacacg	4980
acttatcgcc	actggcagca	gccactggta	acaggattag	cagagcgagg	tatgtaggcg	5040
gtgctacaga	gttcttgaag	tgggtggccta	actacggcta	cactagaagg	acagtatttg	5100
gtatctgcgc	tctgctgaag	ccagttacct	tcggaaaaag	agttggtagc	tcttgatccg	5160
gcaaacaaac	caccgctggt	agcgggtggt	tttttgtttg	caagcagcag	attacgcgca	5220
gaaaaaaagg	atctcaagaa	gatcctttga	tcttttctac	ggggctctgac	gctcagtgga	5280
acgaaaactc	acgttaaggg	attttggtca	tgagattatc	aaaaaggatc	ttcacctaga	5340
tccttttaaa	ttaaaaatga	agttttaaat	caatctaaag	tatatatgag	taaacttgg	5400

ctgacagtta	ccaatgctta	atcagtgagg	cacctatctc	agcgatctgt	ctatttcggt	5460
catccatagt	tgcttgactc	cccgtcgtgt	agataactac	gatacgggag	ggcttaccat	5520
ctggccccag	tgctgcaatg	ataccgcgag	acccacgctc	accggctcca	gatttatcag	5580
caataaacca	gccagccgga	agggccgagc	gcagaagtgg	tcctgcaact	ttatccgcct	5640
ccatccagtc	tattaattgt	tgccgggaag	ctagagtaag	tagttcgcca	gttaatagtt	5700
tgcgcaacgt	tggtgccatt	gctacaggca	tcgtggtgtc	acgctcgtcg	tttggtatgg	5760
cttcattcag	ctccggttcc	caacgatcaa	ggcgagttac	atgatcccc	atggtgtgca	5820
aaaaagcgg	tagctccttc	ggtcctccga	tcgttgtcag	aagtaagttg	gccgcagtg	5880
tatcactcat	ggttatggca	gcactgcata	attctcttac	tgatcatgcca	tcgctaagat	5940
gcttttctgt	gactggtgag	tactcaacca	agtcattctg	agaatagtgt	atgcggcgac	6000
cgagttgtct	ttgcccggcg	tcaatacggg	ataataccgc	gccacatagc	agaactttaa	6060
aagtgtctcat	cattggaaaa	ggttcttcgg	ggcgaaaact	ctcaaggatc	ttaccgctgt	6120
tgagatccag	ttcgatgtaa	cccactcgtg	cacccaactg	atcttcagca	tcttttactt	6180
tcaccagcgt	ttctgggtga	gcaaaaacag	gaaggcaaaa	tgccgcaaaa	aagggaataa	6240
ggcgacacg	gaaatgttga	atactcatac	tcttctcttt	tcaatattat	tgaagcattt	6300
atcagggtta	ttgtctcatg	agcgatatac	tatttgaatg	tatttagaaa	aataaacaaa	6360
taggggttcc	gcgcacattt	ccccgaaaag	tgccacctga	cgtc		6404

<210> 2

<211> 6420

<212> DNA

<213> Artificial Sequence

<220>

<223> vector pVP22/Myc-His-TOPO

<400> 2

gacggatcgg	gagatctccc	gatccccctat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttggtgtgt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180
ttagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgc	tggctgaccg	cccaacgacc	360
cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgcccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggg	aaactgccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgccagta	catgacctta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgctattac	catggtgatg	cggttttggc	agtacatcaa	tgggctgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttg	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaattggcg	780
gtaggcgtgt	acgggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gctggctagt	900
taagcttatt	atgacctctc	gccgctccgt	gaagtccggg	ccgcgggagg	ttccgcgcga	960
tgagtacgag	gatctgtact	acaccccgct	ttcaggtagt	gcgagtcgcc	atagtcgcgc	1020
tgacacctcc	cgccgtggcg	ccctacagac	acgctcgcgc	cagagggggc	aggtccgttt	1080
cgtccagtac	gacgagtcgg	attatgccct	ctacgggggc	tcgtcttcgc	aagacgacga	1140
acacccggag	gtcccccgga	cgcggcgtcc	cgtttccggg	gcggttttgt	ccggcccggg	1200
gcctgcgcgg	gcgcctccgc	cacccgctgg	gtccggaggg	gccggacgca	caccaccac	1260
cgcccccccg	gccccccgaa	cccagcgggt	ggcgactaag	gccccgcgg	ccccggcggc	1320
ggagaccacc	cgcggcagga	aatcggccca	gccagaatcc	gccgcactcc	cagacgcccc	1380
cgctcgacg	gcgccaaccc	gatccaagac	acccgcgcag	gggctggcca	gaaagctgca	1440
ctttagcacc	gcccccccaa	accccgacgc	gccatggacc	ccccgggtgg	ccggctttaa	1500
caagcgctgc	ttctgcgcgc	cggtcgggcg	cctggcgccc	atgcatgccc	ggatggcggc	1560
ggtccagctc	tgggcatagt	cgcgtccgcg	cacagacgaa	gacctcaacg	aactccttgg	1620
catcaccacc	atccgcgtga	cggctctgca	gggcaaaaac	ctgcttcagc	gcgccaacga	1680
gttggtgaat	ccagacgtgg	tgcaggacgt	cgacgcggcc	acggcgactc	gagggcgttc	1740
tgcggcgctc	cgccccaccg	agcgacctcg	agccccagcc	cgtcccgctt	ctcgccccag	1800
acggcccgtc	gagggtagcg	agctcggatc	cactagteca	gtgtgggtgga	attgccctta	1860
agggcaattc	tgcagatata	cagcacagtg	gcggccgctc	gagtctagag	ggcccgcggg	1920
tcgaacaaaa	actcatctca	gaagaggatc	tgaatatgca	taccggtcat	catcaccatc	1980
accattgagt	ttaaaccocg	tgatcagcct	cgaactgtgcc	ttctagttgc	cagccatctg	2040

ttgttttgcgc	ctcccccggtg	ccttccttga	ccttggaagg	tgccactccc	actgtccttt	2100
cctaataaaa	tgaggaaatt	gcctgcatt	gtctgagtag	gtgtcattct	attctggggg	2160
gtgggggtggg	gcaggacagc	aagggggagg	attggaaga	caatagcagg	catgctgggg	2220
atgcggtggg	ctctatggct	tctgaggcgg	aaagaaccag	ctggggctct	aggggggtatc	2280
cccacgcgcc	ctgtagcggc	gcattaaagc	cggcggtgt	ggtggttacg	cgcagcgtga	2340
ccgctacact	tgccagcgcc	ctagcgcggc	ctcctttcgc	ttcttctcct	tcctttctcg	2400
ccacgttcgc	cggtcttccc	cgtcaagctc	taaatcgggg	catcccttta	gggttccgat	2460
ttagtgcttt	acggcacctc	gaccccaaaa	aacttgatta	gggtgatggt	tcacgtagtg	2520
ggccatcgcc	ctgatagacg	gtttttcgcc	ccttgacgtt	ggagtccacg	ttctttaata	2580
gtggactctt	gttccaaact	ggaacaacac	tcaaccttat	ctcggctctat	tccttttgatt	2640
tataagggat	tttggggatt	tgggcctatt	ggttaaaaaa	tgagctgatt	taacaaaaat	2700
ttaacgcgaa	ttaattctgt	ggaatgtgtg	tcagttaggg	tgtggaaagt	cccagggtc	2760
cccaggccagg	cagaagtatg	caaagcatgc	atctcaatta	gtcagcaacc	aggtgtggaa	2820
agtcgccagg	ctccccagca	ggcagaagta	tgcaaaagcat	gcattctcaat	tagtcagcaa	2880
ccatagtcct	gcccctaact	cgccccatcc	cgcctctaac	tcggccaggt	tcggccctatt	2940
ctccgccccca	tggctgacta	atTTTTTTTT	tttatgcaga	ggccgaggcc	gcctctgcct	3000
ctgagctatt	ccagaagtag	tgaggaggct	tttttgaggg	cctaggcttt	tgcaaaaagc	3060
tccggggagc	ttgtatatcc	atTTTtcggat	ctgatcaaga	gacaggatga	ggatcgtttc	3120
gcctgattga	acaagatgga	ttgcacgcag	gttctccggc	cgttggggtg	gagaggctat	3180
tgggtatga	ctgggcacaa	cagacaatcg	gctgctctga	tgcgcgcgtg	ttcgggctgt	3240
cagcgcaggg	gcgcccgggt	ctttttgtca	agaccgacct	gtcgggtgcc	ctgaatgaac	3300
tgcaggacga	ggcagcggg	ctatcgtggc	tggccacgac	ggcggttctt	tgcgcagctg	3360
tgctcgacgt	tgtcactgaa	gcgggaaggg	actggctgct	attgggcgaa	tgccgggggc	3420
aggatctcct	gtcatctcac	cctgctcctg	cggagaaagt	atccatcatg	gctgatgcaa	3480
tgcggcggct	gcatacgctt	gatccggcta	cctgccctatt	cgaccaccaa	gcgaaacatc	3540
gcctcgagcg	agcacgtact	cggatggaag	ccggtcttgt	cgatcaggat	gatctggacg	3600
aagagcatca	ggggctcgcg	ccagccgaac	tgttcgccag	gctcaaggcg	cgcctgcccg	3660
acggcgagga	tctcgtcgtg	acccatggcg	atgcttgctt	gccgaatatc	atggtggaaa	3720
atggcgcgtt	ttctggattc	atcgactgtg	gccggctggg	tgtggcggac	cgtctacagg	3780
acatagcggt	ggctaccggt	gatattgctg	aagagctttg	cggcgaaatg	gctgaccgct	3840
tctcgtgct	ttacggtatc	gcgcgtcccg	attcgacgcg	catgccttc	tatgccttc	3900
ttgacgagtt	cttctgagcg	ggactctggg	gttcgcgaaa	tgaccgacca	agcgacgccc	3960
aaactgccat	cacgagattt	cgattccacc	gccgccttct	atgaaagggt	gggcttcgga	4020
atcgttttcc	gggacgccgg	ctggatgata	ctccagcgcg	gggatctcat	gctggagttc	4080
ttcgccacc	ccaacttggt	tattgcagct	tataatgggt	acaaataaag	caatagcatc	4140
acaaattttca	caaataaagc	atTTTTTTTca	ctgcattcta	gttgtgggtt	gtccaaactc	4200
atcaatgtat	cttatcatgt	ctgtataact	tgcacctcta	gctagagctt	ggcgtaatca	4260
tggtcatagc	tgtttctctg	gtgaaattcg	tatccgctca	caattccaca	caacatacga	4320
gcccgaagca	taaagtgtaa	agcctggggg	gcctaattgag	tgagctaact	cacattaatt	4380
gcgttgcgct	cactgcccgc	tttccagtcg	ggaaacctgt	cgtgccagct	gcattaatga	4440
atcgcccaac	gcgcggggag	aggcggtttg	cgtattgggc	gctcttccgc	ttcctcgctc	4500
actgactcgc	tgcgctcggt	cgttcggctg	cggcgagcgg	tatcagctca	ctcaaaaggcg	4560
gtaatacggg	tatccacaga	atcaggggat	aacgcaggaa	agaacatgtg	agcaaaaggc	4620
cagcaaaagg	ccaggaaccg	taaaaaaggc	gcgttgctgg	cgtttttcca	taggctccgc	4680
ccccctgagc	agcatcacaa	aaactcgacg	tcaagtcaga	tgtggcgaaa	ccgcacagga	4740
ctataaagat	accaggcggt	tccccctgga	agctccctcg	tgctgctctc	tgttccgacc	4800
ctgcgcctta	ccggatacct	gtccgccttt	ctcccttcgg	gaagcgtggc	gctttctcaa	4860
tgctcacgct	gtaggtatct	cagttcgggtg	taggtcgttc	gctccaagct	gggctgtgtg	4920
cacgaacccc	ccgttcagcc	cgaaccgtgc	gccttatccg	gtaactatcg	tccttagctc	4980
aaccgcgtaa	gacacgactt	atcgccactg	gcagcagcca	ctggtaacag	gatttagcaga	5040
gcgagggtatg	taggcgggtg	tacagagtct	ttgaagtggg	ggcctaacta	cggctacact	5100
agaaggacac	tatttgggat	ctcgcgtctg	cgaagccag	ttaccttcgg	aaaaagaggt	5160
ggtagctctt	gatccggcaa	acaaaccacc	ctgtgtacgc	tgtgtttttt	tgtttgcaag	5220
cagcagatta	cgcgcagaaa	aaaaggatct	caagaagatc	ctttgatctt	ttctacgggg	5280
tctgacgctc	agtggaacga	aaactcacgt	taagggtatt	tgggtcatgag	attatcaaaa	5340
aggatcttca	cctagatcct	tttaaattaa	aatgaagtgt	ttaaataaat	ctaaagtata	5400
tatgagtaaa	cttggtctga	cagttaccaa	tgcttaatac	gtgaggcacc	tatctcagcg	5460
atctgtotat	ttcgttcatc	catagttgcc	tgactccccg	tcgtgtagat	aactacgata	5520
cgggagggtc	taccattctgg	ccccagtgtc	gcaatgatac	cgcgagaccc	acgctacccg	5580
gctccagatt	tatcagcaat	aaaccagcca	gccggaaggc	ccgagcgcag	aagtgttctt	5640
qcaactttat	ccgcctccat	ccagtctatt	aattgttggc	gggaagctag	agtaagtagt	5700

```

tcgccagtta atagtttgcg caacgttggt gccattgcta caggcatcgt ggtgtcacgc 5760
tcgtcgtttg gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga 5820
tccccatgt tgtgcaaaaa agcggtttagc tccttcggtc ctccgatcgt tgtcagaagt 5880
aagttggccg cagtgttatc actcatgggt atggcagcac tgcataattc tcttactgtc 5940
atgccatccg taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa 6000
tagtgtatgc ggcgaccgag ttgctcttgc ccggcgtaaa tacgggataa taccgcgcca 6060
catagcagaa ctttaaaaagt gctcatcatt ggaaaacggt cttcggggcg aaaactctca 6120
aggatcttac cgctgttgag atccagttcg atgtaaccca ctcgtgcacc caactgatct 6180
tcagcatctt ttactttcac cagcgtttct ggggtgagcaa aaacaggaag gcaaaatgcc 6240
gcaaaaaagg gaataagggc gacacggaaa tggtgaatac tcatactctt cctttttcaa 6300
tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt 6360
tagaaaaata aacaaatagg ggttcgcgcg acatttcccc gaaaagtgcc acctgacgtc 6420

```

```

<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Peptide linker

```

```

<400> 3
Leu Ala Arg Leu Leu Ala Arg Leu Leu Ala Arg Leu
1           5           10

```

```

<210> 4
<211> 67
<212> PRT
<213> Artificial sequence

```

```

<220>
<223> Conserved sequence of steroid/thyroid hormone
receptor superfamily DNA-binding domain

```

```

<221> VARIANT
<222> (0)...(0)
<223> Xaa is non-conserved amino acids within the
DNA-binding domain

```

```

<221> VARIANT
<222> 7, 9, 11, 13, 22, 27, 58, 61, 66
<223> amino acid residues that are almost universally
conserved, but for which variations have been
found in some identified hormone receptors

```

```

<400> 4
Cys Xaa Xaa Cys Xaa Xaa Asp Xaa Ala Xaa Gly Xaa Tyr Xaa Xaa Xaa
1           5           10           15
Xaa Cys Xaa Xaa Cys Lys Xaa Phe Phe Xaa Arg Xaa Xaa Xaa Xaa
20           25           30
Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Lys
35           40           45
Xaa Xaa Arg Xaa Xaa Cys Xaa Xaa Cys Arg Xaa Xaa Lys Cys Xaa Xaa
50           55           60
Xaa Gly Met
65

```

```

<210> 5
<211> 34
<212> DNA

```

09937837 010700

34

34

34

34

<220>
<223> Peptide linker moiety


```
<210> 12
<211> 14
<212> PRT
<213> Artificial Sequence
```

<400> 12
Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly
1 5 10

```
<210> 13
<211> 18
<212> PRT
<213> Artificial Sequence
```

<220>
<223> Peptide linker moiety

```
<400> 13
Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Ser Gly Ser Thr
  1             5             10             15
Lys Gly
```

```
<210> 14
<211> 14
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Peptide linker moiety
```

<400> 14
Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly
1 5 10

```
<210> 15
<211> 18
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Peptide linker moiety
```

```

<400> 15
Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr
 1           5           10           15
Lys Gly

```

```
<210> 16
<211> 14
<212> PRT
<213> Artificial Sequence
```

<220>

<223> Peptide linker moiety

<400> 16

Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Glu Phe
1 5 10

<210> 17

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker moiety

<400> 17

Ser Arg Ser Ser Gly
1 5

<210> 18

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker moiety

<400> 18

Ser Gly Ser Ser Cys
1 5

<210> 19

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker moiety

<400> 19

Met Gly Arg Ser Gly Gly Gly Cys Ala Gly Asn Arg Val Gly Ser Ser
1 5 10 15
Leu Ser Cys Gly Gly Leu Asn Leu Gln Ala Met
20 25

<210> 20

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Peptide linker moiety

<221> VARIANT

<222> (0)...(0)

<223> Xaa is (GmS)n, where m is
from 2 to 4 and n is from 1 to 11.

<400> 20

Ala Met Xaa Ala Met

009383 010300

5

<211> 16

<213> Dros

Arg Gln :


1

10

15

BOOK REVIEW

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

☐ *Scanned copy is best available.*

Drawing figures are very dark.